Search

Your search keyword '"Vieni, A"' showing total 584 results
Start Over Author "Vieni, A"
584 results on '"Vieni, A"'

153. Primary neuroendocrine carcinoma of the breast: A single Center experience and review of the literature

Author

LOCURTO, Paolo, ANTONA, Angelo Danilo, GRILLO, Antonietta, CIULLA, Antonio, MARTORANA, Stefania, CIPOLLA, Calogero, GRACEFFA, Giuseppa, VIENI, Salvatore, Locurto, P., Antona, A., Grillo, A., Ciulla, A., Martorana, S., Cipolla, C., Graceffa, G., and Vieni, S.

Subjects
Neuroendocrine breast carcinoma, Surgery, Diagnosi
Abstract

Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification. Pathological specimens were stained with hematoxylin and eosin and an immunohistochemical panel of antibodies (Neuron-specific enolase, Chromogranin, Synaptophysin, Estrogen and Progesterone receptors, c-erb and Ki-67). All cases showed markers positivity to Neuron-specific enolase, Chromogranin, Synaptophysin and Estrogen and Progesterone receptors were found. Ki-67 was higher than 40% in four patients. Adjuvant chemotherapy was administrated in patients with Ki-67 > 10%; every patients were treated with radiotherapy and with hormonal therapy too. Although Neuroendocrine breast tumor is considered a distinct entity, the best treatment seems to be correlate to the size of tumor and to the lymph node status and to Ki-67 index like the common breast cancer.

Published
2017

154. Secretory breast carcinoma with metastatic sentinel lymph node

Author

Graceffa Giuseppa, Fricano Salvatore, Cipolla Calogero, Cabibi Daniela, Vieni Salvatore, and Latteri Mario

Subjects
Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Secretory mammary carcinoma is a rare breast neoplasia originally described in children but sometimes also found in adults. It presents a more favourable outcome than more common histological types of breast carcinoma; published literature in fact reports only a few cases with axillary lymph node metastases and only four cases with distant metastases. Clinical presentation In this paper we report a rare case of secretory breast carcinoma with axillary lymph node metastases in a 33-year-old woman. To our knowledge, this is the first case of secretory carcinoma involving biopsy of the sentinel lymph node and investigation of the e-cadherin expression. We found positivity for e-cadherin, which would support the hypothesis that this type of tumour is a variant of the infiltrating ductal carcinoma. Conclusion After a careful analysis of reported data, we have come to the conclusion that the treatment of choice for patients with secretory breast carcinoma should be conservative surgery with sentinel lymph node biopsy, followed by accurate follow-up. We are of the opinion that while post-operative radiotherapy is indicated in adult patients who have undergone quadrantectomy, it should not be used in children. Although several cases of secretory carcinoma have been treated with adjuvant chemotherapy, there are still no reliable data regarding the real value of such a choice.

Published
2006
Full Text
View/download PDF

155. Structure Based Discovery of Pan Active Botulinum Neurotoxin Inhibitors

Author

Desigan Kumaran, Subramaniam Eswaramoorthy, Casey Vieni, Brian E. McGillick, Subramanyam Swaminathan, and Palani Kandavelu

Subjects
0301 basic medicine, Drug discovery, Chemistry, media_common.quotation_subject, medicine.disease, medicine.disease_cause, Microbiology, 03 medical and health sciences, Membrane docking, 030104 developmental biology, medicine, Clostridium botulinum, Botulism, Target protein, SNARE complex, Receptor, Internalization, media_common
Abstract

Clostridium botulinum neurotoxins (BoNTs) released by the bacterium Clostridium botulinum are the most potent toxins causing the fatal disease called botulism. There are seven distinct serotypes of BoNTs (A to G) released by various strains of botulinum. They all have high sequence homology and similar three-dimensional structure. The toxicity of BoNT follows a four-step process–binding, internalization, translocation, and cleavage of its target protein, one of the three components of the SNARE complex (Soluble N-ethylmaleimde-sensitive factor attachment protein receptor) required for membrane docking and neurotransmitter release. Cleavage of one of the three proteins causes blockage of neurotransmitter release leading to flaccid paralysis. Though anyone of the above four steps could be a target for developing antidotes for botulism, the catalytic domain is the most suitable target for post exposure treatment. Of the seven serotypes BoNT/A, B, E and probably F affect humans, with BoNT/A considered to be the most potent. Development of drugs for botulism is focused on serotype specific inhibitors, but pan-active inhibitor acting on several serotypes is preferable since it is difficult to identify the serotype before the treatment, especially since there is at least a 36 h window before botulism can be diagnosed. Using structure-based drug discovery, we have developed three heptapeptides based on the SNARE proteins which inhibit BoNT/A, B and E equally well. Probable reasons for pan-activity of these peptides are discussed.

Published
2018
Full Text
View/download PDF

156. PULMONARY EMBOLISM IN AN EMERGENCY CARE UNIT: EVALUATION OF PREDICTIVE FACTORS FROM CLINICAL HISTORY AND PHYSICAL EXAM

Author

Noto D., Canino B., Vieni S., Graceffa G., Paterno V., Hopps E., Fertitta E., Tinaglia M., Brocato F., Giammanco A., Urso C., Cardella A., Averna M., Squatrito R., Noto D., Canino B., Vieni S., Graceffa G., Paterno V., Hopps E., Fertitta E., Tinaglia M., Brocato F., Giammanco A., Urso C., Cardella A., Averna M., and Squatrito R.

Subjects
Diagnostic score, Pulmonary embolism, Emergency care unit
Abstract

Objective: An early diagnosis of pulmonary embolism (PE) improves outcome. Therefore, PE should be diagnosed in Emergency Care Units (ECU) at admission. Clinical algorithms support the clinician in this task, although performance is biased by differences in risk factors prevalent in different populations. The clinical conditions predictive of PE were evaluated in subjects from Southern Italy accessing ECU for dyspnea/chest pain.Methods: Retrospective clinical data were obtained by electronic retrieving from a hospital database. Data from 8177 patients (age 18-90 years, 54 with PE) were collected from years 2007-2013.Results: Previous history of PE, thrombosis and/or phlebitis, rheumatic diseases, respiratory failure, low blood pressure, pulse oxymetry rate (SpO2) and high heart rate were associated with PE diagnosis. High white blood count with neutrophilia, C reactive protein, D-dimer, NT-pro-BNP determinations, but not troponin T, were associated with PE. Recalibration of the GENEVA score and its modification, by inclusion of novel risk factors, improved the algorithm performance (GENEVA AROC=0.730, modified GENEVA AROC = 0.792, DeLong's test p=

Published
2016

157. The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines

Author

Perez, Alessandro, CASTIGLIA, Marta, PASSIGLIA, Francesco, Barraco, Nadia, Cangemi, Antonina, FANALE, Daniele, LISTI', Angela, Massihnia, Daniela, DI PIAZZA, Florinda, VIENI, Salvatore, CALO', Valentina, RIZZO, Sergio, Incorvaia, L, BAZAN, Viviana, RUSSO, Antonio, Perez, A, Castiglia, M, Passiglia, F, Barraco, N, Cangemi, A, Fanale, D, Listì, A, Massihnia, D, Di Piazza, F, Vieni, S, Calò, V, Rizzo, S, Incorvaia, Bazan, V, and Russo, A

Subjects
Settore MED/06 - Oncologia Medica, microRNAs, miRNAs, EGFR, TKI, resistance, NSCLC
Abstract

Background: the inhibition of EGFR kinase activity by tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, can result in improved response and prolonged progression-free survival (PFS) in NSCLC patients harboring sensitizing exon 19del and exon 21 L858R mutations. Unfortunately, almost all patients will develop resistance to EGFR-TKI, in particular T790M is the most frequent mutation. Nowadays, new methods are urgently needed for a rapid, cost-effective and non-invasive identification of biomarkers as a valuable tool for obtaining the genetic follow-up data during the course of the disease. Circulating microRNAs might represent a new precious biomarker for patients’ monitoring. The study aimed to verify the association between microRNAs expression and EGFR mutational status in adenocarcinoma wt and EGFR-TKI sensitive mutated (del19) cells. Methods: EGFR wt and mutated adenocarcinoma cells (A549, HCC827), were cultured in RPMI1640 and incubated at 37C in 5% CO2. Cell viability before treatment was evaluated by MTT assay and then cells were treated with Erlotinib at growing concentration. MicroRNAs were extracted by using miRNeasy mini kit (QIAGEN). Nucleic acids quantity and quality was evaluated through the NanoDrop ND-2100 Bioanalyzer whereas integrity through the 2100 Bioanalyzer. MicroRNAs after retrotranscription were profiled through TaqMan Array Human MicroRNA Cards v2.0. Results: microRNAs extracted from A549 (wild-type) and HCC827 (del19) were profiled and differential expression analyzed at basal conditions (no treatment) using the wt cell as control. The miRNAs analysis highlighted that among the up-regulated microRNAs (miR-7, miR-18a, miR-106b, miR-200b, miR-505, miR-625), the miR-7 expression levels were 10 times higher, whereas among the down-regulated miRNAs (let-7f, miR-10b, miR-192, miR-193, miR-194, miR-767, miR-801), let-7f was 12 times lower. This signature may represent a valid start point for studying variations of the aforementioned miRNAs levels during TKIs treatment in order to demonstrate their involvement in inducing resistance. Conclusions: to outline molecular mechanisms responsible for resistance onset as consequence of TKIs treatment, the hypotetical role of miRNAs has been studied. The preliminary data, obtained so far only in cultured cell lines at basal conditions, would acquire higher relevance, if their involvement may be confirmed also in TKI-treated cells.

Published
2016

158. ΔNp63 drives metastasis in breast cancer cells via PI3K/CD44v6 axis

Author

Salvatore Vieni, Vincenzo De Laurenzi, Miriam Gaggianesi, Simone Di Franco, Alice Turdo, Jan Paul Medema, Tiziana Apuzzo, Eliana Gulotta, Francesco Dieli, Maria Luisa Colorito, Daniela Barcaroli, Giuseppe Pistone, Antonina Benfante, Matilde Todaro, Laura Rosa Mangiapane, Raju Kandimalla, Aurora Chinnici, Giorgio Stassi, Center of Experimental and Molecular Medicine, CCA -Cancer Center Amsterdam, Radiotherapy, Di Franco, S., Turdo, A., Benfante, A., Colorito, M., Gaggianesi, M., Apuzzo, T., Kandimalla, R., Chinnici, A., Barcaroli, D., Mangiapane, L., Pistone, G., Vieni, S., Gulotta, E., Dieli, F., Medema, J., Stassi, G., De Laurenzi, V., and Todaro, M

Subjects
0301 basic medicine, Gene isoform, Epithelial-Mesenchymal Transition, Breast Neoplasms, medicine.disease_cause, Metastasis, Mice, Phosphatidylinositol 3-Kinases, 03 medical and health sciences, Breast cancer, Tumor Microenvironment, medicine, Animals, Humans, metastasis, Epithelial–mesenchymal transition, Neoplasm Metastasis, PI3K/AKT/mTOR pathway, Aged, Aged, 80 and over, Tumor microenvironment, p63, breast cancer initiating cells, business.industry, Membrane Proteins, CD44v6, Middle Aged, medicine.disease, PI3K/AKT pathway, Hyaluronan Receptors, 030104 developmental biology, Oncology, Drug Resistance, Neoplasm, Tumor progression, Immunology, Cancer research, Female, breast cancer initiating cell, metastasi, business, Carcinogenesis, Proto-Oncogene Proteins c-akt, Signal Transduction, Priority Research Paper
Abstract

P63 is a transcription factor belonging to the family of p53, essential for the development and differentiation of epithelia. In recent years, it has become clear that altered expression of the different isoforms of this gene can play an important role in carcinogenesis. The p63 gene encodes for two main isoforms known as TA and ΔN p63 with different functions. The role of these different isoforms in sustaining tumor progression and metastatic spreading however has not entirely been clarified. Here we show that breast cancer initiating cells express ΔNp63 isoform that supports a more mesenchymal phenotype associated with a higher tumorigenic and metastatic potential. On the contrary, the majority of cells within the tumor appears to express predominantly TAp63 isoform. While ΔNp63 exerts its effects by regulating a PI3K/CD44v6 pathway, TAp63 modulates this pathway in an opposite fashion. As a result, tumorigenicity and invasive capacity of breast cancer cells is a balance of the two isoforms. Finally, we found that tumor microenvironmental cytokines significantly contribute to the establishment of breast cancer cell phenotype by positively regulating ΔNp63 and CD44v6 expression.

Published
2016

163. Hashimoto Thyroiditis Coexistent with Papillary Thyroid Carcinoma

Author

CIPOLLA, C, FRICANO, S, CIPOLLA, Calogero, LATTERI, S, SANDONATO, Luigi, GRACEFFA, Giuseppa, TORCIVIA, Adriana, VIENI, Salvatore, LATTERI, Mario, CIPOLLA, C, SANDONATO, L, GRACEFFA, G, FRICANO, S, TORCIVIA, A, VIENI, S, LATTERI, S, and LATTERI, M

Subjects
Adult, Male, endocrine system, medicine.medical_specialty, Pathology, Goiter, thyroid tumor, endocrine system diseases, retrospective study, medicine.medical_treatment, Hashimoto Disease, thyroidectomy MeSH: Adenocarcinoma, Papillary, Gastroenterology, Thyroid carcinoma, Retrospective Studie, Internal medicine, medicine, Humans, human, Thyroid Neoplasms, Thyroid cancer, Thyroid Neoplasm, Aged, Retrospective Studies, Autoimmune disease, adenocarcinoma, adult, aged, article, female, Hashimoto disease, male, middle aged, thyroidectomy Adenocarcinoma, Papillary, Female, Middle Aged, Thyroidectomy [EMTREE medical terms], business.industry, Thyroidectomy, General Medicine, medicine.disease, Major duodenal papilla, Adenocarcinoma, Papillary, Immunohistochemistry, Adenocarcinoma, business, EMTREE medical terms: adenocarcinoma
Abstract

Several studies report a higher rate of papillary thyroid carcinomas (PTC) in patients with Hashimoto thyroiditis (HT), indicating a possible correlation between the two diseases. We studied a group of 89 subjects undergoing surgery for thyroid carcinomas compared with a control group of 89 subjects operated on for normofunctioning goiter, and a second group of 47 patients undergoing total thyroidectomy for HT. Association with HT was found in 19 of the 71 PTC subjects (26.7%) and in 8 goiter patients (8.9%), which was a significant difference ( P < 0.02). Thirteen of the HT patients, mostly with the nodular form, showed coexistent PTC (27.6%). HT and PTC coexisted in several morphological, immunohistochemical, and biomolecular aspects; increased incidence of PTC in HT patients might therefore indicate that HT is a precursor of thyroid cancer. Further studies are required, however, in order to confirm this hypothesis; until then, HT patients should undergo careful clinical and technical follow-up.

Published
2005
Full Text
View/download PDF

168. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma

Author

Cipolla, C., Graceffa, G., La Mendola, R., Fricano, S., Fricano, M., Vieni, S., Cipolla, C., Graceffa, G., La Mendola, R., Fricano, S., Fricano, M., and Vieni, S.

Subjects
Adult, Neoplasms, Hormone-Dependent, Biopsy, Fine-Needle, Breast carcinoma, Breast Neoplasms, Humans, Radionuclide Imaging, Technetium Tc 99m Aggregated Albumin, Mastectomy, Aged, Retrospective Studies, Aged, 80 and over, Sentinel Lymph Node Biopsy, Carcinoma, Ductal, Breast, Micrometase, Middle Aged, Prognosis, Combined Modality Therapy, Carcinoma, Lobular, Neoplasm Micrometastasis, Lymphatic Metastasis, Micrometases, Sentinel lymph node, Surgery, Axilla, Lymph Node Excision, Female, Neoplasm Recurrence, Local, Radiopharmaceuticals
Abstract

The prognostic value of sentinel lymph node micrometastases in invasive breast cancer patients is still widely debated. Even if, in the absence of unequivocal guidelines, the axillary lynphadenectomy is not still performed in the routine clinical care of these patients.We have retrospectively analyzed 746 patients with operable invasive breast cancer and clinically negative axillary lymph nodes. These patients underwent conservative surgery or total mastectomy with sentinel lymph node biopsy. Patients with micrometastases in the sentinel lymph node treated with axillary dissection has been checked and the involvement of the remaining lymph nodes analyzed. Patients with micrometastases in the SLN not followed by axillary dissection have been checked as well and the incidence of recurrences has been evaluated in both groups.Micrometastases were found in 51 (6.83%) patients and isolated tumor cells in 8 (1.07%) patients at frozen section and confirmed at the final hystopathologic examination. Fifteen of these patients underwent complete axillary dissection: two of them (13.33%) had metastatic involvement of other axillary lymph nodes. The other 44 patients didn't receive further surgical axillary procedure. No axillary recurrences in these patients were found during a median follow up of 65.3±9.65 months (range 42-78 months).Based on the results and according to some recent randomized trials we can say that axillary lynphadenectomy can be avoided when micrometastases are found in sentinel lynph nodes. It should be performed anyway, depending on the analysis of the biomedical profile of the tumor.Breast carcinoma, Micrometases, Sentinel lymph node.Il significato prognostico delle micrometastasi nel linfonodo sentinella nelle pazienti affette da carcinoma della mammella è ancora ampiamente dibattuto. Anche se, in assenza di univoche linee guida, nella pratica clinica la linfadenectomia ascellare in queste pazienti non viene più eseguita di routine. Abbiamo condotto uno studio retrospettivo su 746 patienti affette da carcinoma invasivo della mammella con linfonodi ascellari negativi, sottoposte a chirurgia conservativa o a mastectomia totale con biopsia del linfonodo sentinella. Le pazienti in cui è stata diagnostica la presenza di micrometastasi del linfonodo sentinella sono state considerate in due diversi gruppi. In un primo gruppo, trattato con linfadenectomia ascellare totale è stata valutata l’incidenza di metastasi a carico dei rimanenti linfonodi ascellari. Un secondo gruppo non ha ricevuto alcun trattamento aggiuntivo dell’ascella e le pazienti sono state seguite con controlli periodici clinico strumentali. In entrambi i gruppi è stata valutata l’incidenza di eventuali recidive ascellari. All’esame istologico estemporaneo ed al successivo esame istologico definitivo del linfonodo sentinella, in 51 pazienti (6,83%) sono state evidenziate micrometastasi, in 8 pazienti (1,07%) erano presenti cellule tumorali isolate. Quindici di queste pazienti sono state sottoposte a linfadenectomia ascellare totale. Solo in 2 casi (13,33%) sono state ritrovate metastasi a carico dei rimanenti linfonodi ascellari. Quarantaquattro pazienti non hanno ricevuto alcun trattamento aggiuntivo dell’ascella. In queste pazienti nessuna recidiva ascellare è stata registrata durante un follow-up medio di 65,3±9,65 mesi (range 42-78 mesi). Sulla base dei risultati ottenuti in questo studio ed in linea con alcuni recenti trials randomizzati si ci sentiamo di concludere che la linfadenectomia ascellare può essere evitata nei casi con micrometastasi nel linfonodo sentinella. Una sua eventuale indicazione può essere valutata caso per caso considerando come fattori di rischio per la recidiva ascellare alcune caratteristiche biomorfologiche del tumore primitivo.

Published
2015

169. Nuclear cardiology practice in Asia: Analysis of radiation exposure and best practice for myocardial perfusion imaging ― results from the IAEA nuclear cardiology protocols cross-sectional study (INCAPS)

Author

Pascual, Tnb, Mercuri, M, El-Haj, N, Hee-Sung Bom, H, Lele, V, Al-Mallah, Mh, Luxenburg, O, Karthikeyan, G, Vitola, Jv, Mahmarian, Jj, Better, N, Shaw, Lj, Rehani, Mm, Kashyap, R, Paez, D, Dondi, M, Eistein, Aj, Bouyoucef, Salah E., Allam, Adel H., Vangu, Mboyo, Magboo, V. P. C., Mut, F., Alexánderson, E., Allam, A., Bom, H., Flotats, A., Jerome, S., Kaufmann, P. A., Underwood, S. R., Vitola, J., Amouri, W., Essabbah, H., Gassama, S. S., Makhdomi, K. B., El Mustapha, G. I. E., El Ouchdi, N., Qaïs, N., Soni, N., Vangu, W., Abazid, R. M., Adams, B., Agarwal, V., Alfeeli, M. A., Alnafisi, N., Bernabe, L., Bural, G. G., Chaiwatanarat, T., Chandraguptha, J. M., Cheon, G. J., Cho, I., Dogan, A. S., Eftekhari, M., Frenkel, A., Garty, I., George, S., Geramifar, P., Golan, H., Habib, S., Hussain, R., Im, H., Jeon, H. -J., Kalawat, T., Kang, W. J., Keng, F., Klaipetch, A., Kumar, P. G., Lee, J., Lee, W. W., Lim, I., Macaisa, C. M. M., Malhotra, G., Mittal, B. R., Mohammad, M. H., Mohan, P., Mulyanto, I. D., Nariman, D., Nayak, U. N., Niaz, K., Nikolov, G., Obaldo, J. M., Ozturk, E., Park, J. M., Park, S., Patel, C. D., Phuong, H. K., Quinon, A. P., Rajini, T. R., Saengsuda, Y., Santiago, J., Sayman, H. B., Shinto, A. S., Sivasubramaniyan, V., Son, M. H., Sudhakar, P., Syed, G. M. S., Tamaki, N., Thamnirat, K., Thientunyakit, T., Thongmak, S., Velasco, D. N., Verma, A., Vutrapongwatana, U., Wang, Y., Won, K. S., Yao, Z., Yingsa-Nga, T., Yudistiro, R., Yue, K. T., Zafrir, N., Adrian, S. C., Agostini, D., Aguadé, S., Armitage, G., Backlund, M., Backman, M., Baker, M., Balducci, M. T., Bavelaar, C., Berovic, M., Bertagna, F., Beuchel, R., Biggi, A., Bisi, G., Bonini, R., Bradley, A., Brudin, L., Bruno, I., Busnardo, E., Casoni, R., Choudhri, A., Cittanti, C., Clauss, R., Costa, D. C., Costa, M., Dixon, K., Dziuk, M., Egelic, N., Eriksson, I., Fagioli, G., De Faria, D. B., Florimonte, L., Francini, A., French, M., Gallagher, E., Garai, I., Geatti, O., Genovesi, D., Gianolli, L., Gimelli, A., Del Giudice, E., Halliwell, S., Hansson, M. J., Harrison, C., Homans, F., Horton, F., Jȩdrzejuk, D., Jogi, J., Johansen, A., Johansson, H., Kalnina, M., Kaminek, M., Kiss, A., Kobylecka, M., Kostkiewicz, M., Kropp, J., Kullenberg, R., Lahoutte, T., Lang, O., Larsson, Y. H., Lázár, M., Leccisotti, L., Leners, N., Lindner, O., Lipp, R. W., Maenhout, A., Maffioli, L., Marcassa, C., Martins, B., Marzullo, P., Medolago, G., Mendiguchía, C. G., Mirzaei, S., Mori, M., Nardi, B., Nazarenko, S., Nikoletic, K., Oleksa, R., Parviainen, T., Patrina, J., Peace, R., Pirich, C., Piwowarska-Bilska, H., Popa, S., Prakash, V., Pubul, V., Puklavec, L., Rac, S., Ratniece, M., Rogan, S. A., Romeo, A., Rossi, M., Ruiz, D., Sabharwal, N., Salobir, B. G., Santos, A. I., Saranovic, S., Sarkozi, A., Schneider, R. P., Sciagra, R., Scotti, S., Servini, Z., Setti, L. R., Starck, S-Ã…., Vajauskas, D., Veselý, J., Vieni, A., Vignati, A., Vito, I. M., Weiss, K., Wild, D., Zdraveska-Kochovska, M., Agüro, R. N., Alvarado, N., Barral, C. M., Beretta, M., Berrocal, I., Batista Cuellar, J. F., Cabral Chang, T. -M., Cabrera Rodríguez, L. O., Canessa, J., Castro Mora, G., Claudia, A. C., Clavelo, G. F., Cruz, A. F., Faccio, F. F., Fernández, K. M., Gomez Garibo, J. R., Gonzalez, U., González, P. E., Guzzo, M. A., Jofre, J., Kapitán, M., Kempfer, G., Lopez, J. L., Massardo, T. V., Medeiros Colaco, I., Mesquita, C. T., Montecinos, M., Neubauer, S., Pabon, L. M., Puente, A., Rochela Vazquez, L. M., Serna Macias, J. A., Silva Pino, A. G., Tártari Huber, F. Z., Tovar, A. P., Vargas, L., Wiefels, C., Aljizeeri, A., Alvarez, R. J., Barger, D., Beardwood, W., Behrens, J., Brann, L., Brown, D., Carr, H., Churchwell, K., Comingore, G. A., Corbett, J., Costello, M., Cruz, F., Depinet, T., Dorbala, S., Earles, M., Esteves, F. P., Etherton, E., Fanning, R. J., Fornace, J., Franks, L., Gewirtz, H., Gulanchyn, K., Hannah, C. -L., Hays, J., Hendrickson, J., Hester, J., Holmes, K., Johnson, A., Jopek, C., Lewin, H., Lyons, J., Manley, C., Meden, J., Moore, S., Moore, W. H., Murthy, V., Nace, R., Neely, D., Nelson, L., Niedermaier, O., Rice, D., Rigs, R., Schiffer, K., Schockling, E., Schultz, T., Schumacker, T., Sheesley, B., Sheikh, A., Siegel, B., Slim, A. M., Smith, J., Szulc, M. C., Tanskersley, N., Tilkemeier, P., Valdez, G. D., Vrooman, R., Wawrowicz, D., Winchester, D. E., Alcheikh, A., Allen, B., Atkins, E., Bevan, J., Bonomini, C., Christiansen, J., Clack, L., Craig, E., Dixson, H., Duncan, I., Fredericks, S., Gales, S., Hampson, R., Hanley, T., Hartcher, K., Hassall, J., Kelley, B., Kelly, S., Kidd, T., De Kort, T., Larcos, G., Macdonald, W., Mcgrath, C., Murdoch, E., O'Malley, S., O'Rourke, M., Pack, M., Pearce, R., Praehofer, R., Ramsay, S., Scarlett, L., Smidt, K., Souvannavong, F., Taubman, K., Taylor, G., Tse, K., Unger, S., and Weale, J.

Subjects
Male, medicine.medical_specialty, Asia, Cross-sectional study, Best practice, Cardiology, Practice Patterns, 030204 cardiovascular system & hematology, Radiation Dosage, Effective dose (radiation), 030218 nuclear medicine & medical imaging, NO, 03 medical and health sciences, Myocardial perfusion imaging, 0302 clinical medicine, medicine, Humans, Medical physics, Dosing, Practice Patterns, Physicians', Quality of care, Thallium, Aged, Quality of Health Care, Radiation, Physicians', medicine.diagnostic_test, business.industry, Radiation dose, Technetium, Nuclear cardiology, General Medicine, Middle Aged, Radiation Exposure, Radiation exposure, Cross-Sectional Studies, Female, Nuclear Medicine, Cardiology and Cardiovascular Medicine, business, Myocardial Perfusion Imaging
Abstract

BACKGROUND This paper examines the current status of radiation exposure to patients in myocardial perfusion imaging (MPI) in Asia.Methods and Results:Laboratories voluntarily provided information on MPI performed over a 1-week period. Eight best practice criteria regarding MPI were predefined by an expert panel. Implementation of ≥6 best practices (quality index [QI] ≥6) was pre-specified as a desirable goal for keeping radiation exposure at a low level. Radiation effective dose (ED) in 1,469 patients and QI of 69 laboratories in Asia were compared against data from 239 laboratories in the rest of the world (RoW). Mean ED was significantly higher in Asia (11.4 vs. 9.6 mSv; P

Published
2017

170. Nuclear Cardiology Practices and Radiation Exposure in the Oceania Region: results From the IAEA Nuclear Cardiology Protocols Study (INCAPS)

Author

Biswas, S, Better, N, Pascual, TNB, Mercuri, M, Vitola, JV, Karthikeyan, G, Westcott, J, Alexanderson, E, Allam, AH, Al-Mallah, MH, Bom, HHS, Bouyoucef, SE, Flotats, A, Jerome, S, Kaufman, PA, Lele, V, Luxenburg, O, Mahmarian, JJ, Shaw, LJ, Underwood, SR, Rehani, M, Kashyap, R, Dondi, M, Paez, D, Einstein, AJ, Alcheikh, A, Allen, B, Kelley, B, Bonomini, C, McGrath, C, Atkins, E, Craig, E, Murdoch, E, Souvannavong, F, Larcos, G, Taylor, G, Dixson, H, Duncan, I, Bevan, J, Christiansen, J, Hassall, J, Weale, J, Hartcher, K, Smidt, K, Taubman, K, Tse, K, Clark, L, Scarlett, L, O'Rourke, M, Pack, M, Hampson, R, Pearce, R, Praehofer, R, Fredericks, S, Gales, S, Kelly, S, O'Malley, S, Ramsay, S, Unger, S, de Kort, T, Hanley, T, Kidd, T, Macdonald, W, Magboo, VPC, Mut, F, Meeks, JB, Rehani, MM, Allam, A, Bom, H, Kaufmann, PA, Mahmarian, J, Vitola, J, Amouri, W, Essabbah, H, Gassama, SS, Makhdomi, KB, El Mustapha, GIE, El Ouchdi, N, Qais, N, Soni, N, Vangu, W, Abazid, RM, Adams, B, Agarwal, V, Alfeeli, MA, Alnafisi, N, Bernabe, L, Bural, GG, Chaiwatanarat, T, Chandraguptha, JM, Cheon, GJ, Cho, I, Dogan, AS, Eftekhari, M, Frenkel, A, Garty, I, George, S, Geramifar, P, Golan, H, Habib, S, Hussain, R, Im, H, Jeon, HJ, Kalawat, T, Kang, WJ, Keng, F, Klaipetch, A, Kumar, PG, Lee, J, Lee, WW, Lim, I, Macaisa, CMM, Malhotra, G, Mittal, BR, Mohammad, MH, Mohan, P, Mulyanto, ID, Nariman, D, Nayak, UN, Niaz, K, Nikolov, G, Obaldo, JM, Ozturk, E, Park, JM, Park, S, Patel, CD, Phuong, HK, Quinon, AP, Rajini, TR, Saengsuda, Y, Santiago, J, Sayman, HB, Shinto, AS, Sivasubramaniyan, V, Son, MH, Sudhakar, P, Syed, GMS, Tamaki, N, Thamnirat, K, Thientunyakit, T, Thongmak, S, Velasco, DN, Verma, A, Vutrapongwatana, U, Wang, Y, Won, KS, Yao, Z, Yingsa-Nga, T, Yudistiro, R, Yue, KT, Zafrir, N, Adrian, SC, Agostini, D, Aguade, S, Armitage, G, Backlund, M, Backman, M, Baker, M, Balducci, MT, Bavelaar, C, Berovic, M, Bertagna, F, Beuchel, R, Biggi, A, Bisi, G, Bonini, R, Bradley, A, Brudin, L, Bruno, I, Busnardo, E, Casoni, R, Choudhri, A, Cittanti, C, Clauss, R, Costa, DC, Costa, M, Dixon, K, Dziuk, M, Egelic, N, Eriksson, I, Fagioli, G, de Faria, DB, Florimonte, L, Francini, A, French, M, Gallagher, E, Garai, I, Geatti, O, Genovesi, D, Gianolli, L, Gimelli, A, del Giudice, E, Halliwell, S, Hansson, MJ, Harrison, C, Homans, F, Horton, F, Jedrzejuk, D, Jogi, J, Johansen, A, Johansson, H, Kalnina, M, Kaminek, M, Kiss, A, Kobylecka, M, Kostkiewicz, M, Kropp, J, Kullenberg, R, Lahoutte, T, Lang, O, Larsson, YH, Lazar, M, Leccisotti, L, Leners, N, Lindner, O, Lipp, RW, Maenhout, A, Maffioli, L, Marcassa, C, Martins, B, Marzullo, P, Medolago, G, Mendiguchia, CG, Mirzaei, S, Mori, M, Nardi, B, Nazarenko, S, Nikoletic, K, Oleksa, R, Parviainen, T, Patrina, J, Peace, R, Pirich, C, Piwowarska-Bilska, H, Popa, S, Prakash, V, Pubul, V, Puklavec, L, Rac, S, Ratniece, M, Rogan, SA, Romeo, A, Rossi, M, Ruiz, D, Sabharwal, N, Salobir, BG, Santos, AI, Saranovic, S, Sarkozi, A, Schneider, RP, Sciagra, R, Scotti, S, Servini, Z, Setti, LR, Starck, SA, Vajauskas, D, Vesely, J, Vieni, A, Vignati, A, Vito, IM, Weiss, K, Wild, D, Zdraveska-Kochovska, M, Aguro, RN, Alvarado, N, Barral, CM, Beretta, M, Berrocal, I, Cuellar, JFB, Chang, TMC, Rodriguez, LOC, Canessa, J, Mora, GC, Claudia, AC, Clavelo, GF, Cruz, AF, Faccio, FF, Fernandez, KM, Garibo, JRG, Gonzalez, U, Gonzalez, P, Guzzo, MA, Jofre, J, Kapitan, M, Kempfer, G, Lopez, JL, Massardo, TV, Colaco, IM, Mesquita, CT, Montecinos, M, Neubauer, S, Pabon, LM, Puente, A, Vazquez, LMR, Macias, JAS, Pino, AGS, Huber, FZT, Tovar, AP, Vargas, L, Wiefels, C, Aljizeeri, A, Alvarez, RJ, Barger, D, Beardwood, W, Behrens, J, Brann, L, Brown, D, Carr, H, Churchwell, K, Comingore, GA, Corbett, J, Costello, M, Cruz, F, Depinet, T, Dorbala, S, Earles, M, Esteves, FP, Etherton, E, Fanning, RJ, Fornace, J, Franks, L, Gewirtz, H, Gulanchyn, K, Hannah, CL, Hays, J, Hendrickson, J, Hester, J, Holmes, K, Johnson, A, Jopek, C, Lewin, H, Lyons, J, Manley, C, Meden, J, Moore, S, Moore, WH, Murthy, V, Nace, R, Neely, D, Nelson, L, Niedermaier, O, Rice, D, Rigs, R, Schiffer, K, Schockling, E, Schultz, T, Schumacker, T, Sheesley, B, Sheikh, A, Siegel, B, Slim, AM, Smith, J, Szulc, M, Tanskersley, N, Tilkemeier, P, Valdez, GD, Vrooman, R, Wawrowicz, D, Winchester, DE, Dixon, H, and INCAPS Investigators Grp

Subjects
Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Oceania, 030204 cardiovascular system & hematology, Radiation Dosage, Effective dose (radiation), Sievert, 030218 nuclear medicine & medical imaging, NO, 03 medical and health sciences, Myocardial perfusion imaging, Radiation exposure, Aged, Female, Humans, Middle Aged, Myocardial Perfusion Imaging, Radiation Exposure, 0302 clinical medicine, Internal medicine, medicine, medicine.diagnostic_test, business.industry, Radiation dose, Cardiology, Cardiology and Cardiovascular Medicine, business
Abstract

Background There is concern about radiation exposure with radionuclide myocardial perfusion imaging (MPI). This sub-study of the International Atomic Energy Agency (IAEA) Nuclear Cardiology Protocols Study reports radiation doses from MPI, and use of dose-optimisation protocols in Australia and New Zealand (ANZ), and compares them with data from the rest of the world. Methods Data were collected from 7911 MPI studies performed in 308 laboratories worldwide in one week in 2013, including 439 MPI studies from 34 ANZ laboratories. For each laboratory, effective radiation dose (ED) and a quality index (QI) score (out of 8) based on pre-specified "best practices'' was determined. Results In ANZ patients, ED ranged from 0.9-17.9 milliSievert (mSv). Median ED was similar in ANZ compared with the rest of the world (10.0 (IQR: 6.5-11.7) vs. 10.0 (IQR 6.4-12.6, P=0.15), as were mean QI scores (5.5 +/- 0.7 vs. 5.4 +/- 1.3, P= 0.84). Use of stress-only imaging (17.6% vs. 31.8% of labs, P= 0.09) and weight-based dosing of technetium-99m (14.7% vs. 30.3%, P= 0.07) was lower in ANZ compared with the rest of the world but this difference was not statistically significant. Median ED was significantly lower in metropolitan versus nonmetropolitan laboratories (10.1 mSv vs. 11.6 mSv, P < 0.01), although mean QI scores were similar (5.4 +/- 0.8 vs. 5.5 +/- 0.7, P= 0.75). Conclusion Across ANZ, there is variability in ED from MPI, and use of radiation safety practices, particularly between metropolitan and non-metropolitan laboratories. Overall, ANZ laboratories have a similar median ED to laboratories in the rest of the world.

Published
2017

172. ROLE OF NAKED CUTICLE HOMOLOG 1 GENE ON CHR 16Q12 IN INFLAMMATORY BOWEL DISEASE

Author

Latiano, Anna, Palmieri, Orazio, Valvano, Maria R., D Inca, Renata, Guariso, Graziella, Vieni, Giuseppe, Roberto Berni Canani, Accomando, Salvatore, Catassi, Carlo, Angelis, Gian L., Castro, Massimo, Cucchiara, Salvatore, Ancona, Nicola, Andriulli, Angelo, Annese, Vito, A., Latiano, O., Palmieri, M., Valvano, R., D'Incà, G., Guariso, G., Vieni, BERNI CANANI, Roberto, S., Accomando, C., Catassi, G., de Angeli, M., Castro, S., Cucchiara, N., Ancona, A., Andriulli, V. A. n. n. e. s., E., Latiano, A, Palmieri, O, Valvano, M, D’Incà, R, Guariso, G, Vieni, G, Berni Canani, R, Accomando, S, Catassi, C, de Angelis, G, Castro, M, Cucchiara, S, Ancona, N, Andriulli, A, and Annese, V

Subjects
Settore MED/38 - Pediatria Generale E Specialistica, IBD Genetics
Published
2010

173. The Importance of Disease Prevalence in Assessing the Diagnostic Value of a Test: Endoscopic Markers in Celiac Disease

Author

Giovanni Tuccari, Guido Passanisi, Giuseppe Vieni, Federica Furfaro, Vincenzo Villanacci, Gabrio Bassotti, Concetta Sferlazzas, Lidia Puzzo, Nunzio Belluardo, Stefano Costa, Aldina Bertone, Andrea Tortora, Sebastiana Malandrino, Giuseppe Magazzù, Cinzia D'Agate, Luigi Familiari, Salvatore Pellegrino, M. Spina, Agata Sciacca, Giovanni Currò, and Pietro Naso

Subjects
Adult, Male, medicine.medical_specialty, Malattia celiaca, studio prospettico, Adolescent, Duodenum, education, Prevalence, Disease, endoscopia, Gastroenterology, Young Adult, Internal medicine, medicine, Humans, Prospective Studies, Child, Celiac disease, Diagnostic tests, Disease prevalence, Endoscopy, Duodenoscopy, Aged, Aged, 80 and over, Reproducibility, medicine.diagnostic_test, business.industry, Infant, Reproducibility of Results, nutritional and metabolic diseases, Diagnostic test, Endoscopy, Middle Aged, digestive system diseases, Test (assessment), Celiac Disease, Italy, Diagnostic tests, Child, Preschool, Female, business, human activities, Value (mathematics), Disease prevalence, Biomarkers
Abstract

Background/Aims: We evaluated the diagnostic variability and reproducibility of endoscopic signs in two populations with a different pretest likelihood of celiac disease (CD). Methods: We recruited 289 CD patients (both adults and children) in a multicenter prospective study. Group 1 (high risk) included 111 patients referred for positive serology. Group 2 (low risk) included 178 unselected patients. Mosaic pattern, reduction/loss of Kerckring's folds, scalloping of the valvulae conniventes and a nodular pattern were the endoscopic findings looked for in the duodenum. Results: In group 1, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of endoscopic findings were 100, 84.6, 94.2 and 100% in adults, and 86.8, 9.1, 82.1 and 12.5% in children. In group 2, the sensitivity, specificity, PPV and NPV of endoscopic findings were 33.3, 91.4, 7.7 and 98.5% in adults, and noncalculable, 78.3, 0.0 and 100% in children. Comparing group 1 and group 2, there was a statistically significant difference in sensitivity and PPV in adults, and in specificity, PPV and NPV in children. Concerning the reproducibility of endoscopic findings, a wide variability of κ values was found. Conclusion: Endoscopic signs have low reproducibility for CD, and their diagnostic value in selecting patients for multiple intestinal biopsies is unacceptable, especially in populations with low disease prevalence.

Published
2013
Full Text
View/download PDF

174. Contents Vol. 87, 2013

Author

Yuki Okado, Tsutomu Nishida, Takahiro Inoue, Byung-Hoon Min, Yasuhiro Takaki, Jahangir Khan, Xavier Pepermans, Giuseppe Magazzù, Hiroshi Watanabe, Jong Chul Rhee, Akira Mukai, Takashi Nagahama, Andrea Tortora, Nunzio Belluardo, Stefano Costa, Yu Matsushima, Anne Jouret-Mourin, Pietro Naso, Julia Martin, Juhani Sand, Hubert Piessevaux, Noritaka Takatsu, Yoichiro Ono, Mihoko Yamade, Massimo Spina, Aldina Bertone, Teresinha Leal, Yuho Sato, Kozue Tsurumi, Takanori Yamada, Concetta Sferlazzas, Satoshi Osawa, Jürgen Stein, Jae J. Kim, Kathrin Krieger, Luigi Familiari, Takahisa Furuta, Birgit Weynand, Akinori Iwashita, Satoshi Ishikawa, Pierre Henri Deprez, Masafumi Nishino, Druck Reinhardt Druck Basel, Shoko Fujiwara, Jun Haeng Lee, Yutaka Yano, Kyoung-Mee Kim, Fumihito Hirai, Giovanni Currò, Toshiyuki Matsui, Tabea Geisel, Syoichiro Kawai, André Geubel, Guido Passanisi, Ken Sugimoto, Poong-Lyul Rhee, Sebastiana Malandrino, Eun Ran Kim, Jean-Baptiste Habyalimana, Takahiro Beppu, Shu Sahara, Coralie Hamoir, Takuya Yamada, Gabrio Bassotti, Satoshi Hiyama, Takashi Hisabe, Isto Nordback, Eri Shiraishi, Hideki Iijima, Giovanni Tuccari, Agata Sciacca, Constanze Christin Maresch, Masahiko Tsujii, Jean-François Gigot, Mitsushige Sugimoto, Tetsuo Takehara, Lidia Puzzo, Yang Won Min, Kazuo Umemura, Vincenzo Villanacci, Naoyuki Yoshizawa, Takahiro Uotani, Federica Furfaro, Hiroaki Miyajima, Cinzia D'Agate, Giuseppe Vieni, Kenshi Yao, Shinichiro Shinzaki, and Salvatore Pellegrino

Subjects
Gastroenterology
Published
2013
Full Text
View/download PDF

175. Primary neuroendocrine carcinoma of the breast A single Center experience and review of the literature

Author

Paolo, Locurto, Angelo Danilo, Antona, Antonietta, Grillo, Antonio, Ciulla, Stefania, Martorana, Calogero, Cipolla, Giuseppa, Graceffa, and Salvatore, Vieni

Subjects
Receptors, Steroid, Neoplasms, Hormone-Dependent, Sentinel Lymph Node Biopsy, Breast Neoplasms, Estrogens, Middle Aged, Combined Modality Therapy, Carcinoma, Neuroendocrine, Neoplasm Proteins, Radiotherapy, High-Energy, Tamoxifen, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Female, Radiotherapy, Adjuvant, Cisplatin, Mastectomy, Progesterone, Aged, Etoposide, Retrospective Studies
Abstract

Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification. Pathological specimens were stained with hematoxylin and eosin and an immunohistochemical panel of antibodies (Neuron-specific enolase, Chromogranin, Synaptophysin, Estrogen and Progesterone receptors, c-erb and Ki-67). All cases showed markers positivity to Neuron-specific enolase, Chromogranin, Synaptophysin and Estrogen and Progesterone receptors were found. Ki-67 was higher than 40% in four patients. Adjuvant chemotherapy was administrated in patients with Ki-6710%; every patients were treated with radiotherapy and with hormonal therapy too. Although Neuroendocrine breast tumor is considered a distinct entity, the best treatment seems to be correlate to the size of tumor and to the lymph node status and to Ki-67 index like the common breast cancer.Diagnosis, Neuroendocrine breast carcinoma.Il carcinoma neuroendocrino della mammella è un tumore estremamente raro. I casi riportati in letteratura sono molto pochi per cui la pianificazione del trattamento è ancora in discussione. Gli Autori riportano la loro esperienza su 5 casi osservati tra gennaio 2007 e dicembre 2014, insieme ad una revisione della letteratura. Quattro pazienti sono state sottoposte a quadrantectomia, in due delle quali è stata eseguita anche la linfadenectomia ascellare; in un solo caso è stata eseguita una mastectomia totale con linfadenectomia ascellare. In tutti i casi è stata utilizzata la colorazione con ematossilina-eosina ed è stata eseguita la valutazione immunoistochimica della enolasi neuronospecifica (NSE), cromogranina, sinaptofisina, recettori per estrogeni e per progesterone, c-erb e Ki-67. In tutti i casi è stata evidenziata una positività per enolasi neuronospecifica (NSE), cromogranina, sinaptofisina, recettori per estrogeni e per progesterone. In 4 pazienti il valore del Ki-67 era40%. Una chemioterapia adiuvante è stata somministrata nei casi con Ki-6710%; tutte le pazienti sono state sottoposte a radioterapia sulla mammella operata ed hanno effettuato ormonoterapia. Nonostante il tumore neuroendocrino della mammella sia considerato una entità distinta, il trattamento più adeguato sembra essere correlato alle dimensioni del tumore, allo status linfonodali ed al Ki-67, come per gli altri istotipi di carcinoma della mammella.

Published
2016

176. The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines

Author

Perez, Castiglia, A., Passiglia, M., Barraco, F., Cangemi, N., Fanale, A., Listì, D., Massihnia, A., Di Piazza, D., Vieni, F., Calò, S., Rizzo, V., Incorvaia, S., Bazan, L., and Russo, V.

Subjects
Settore MED/06 - Oncologia Medica, microRNAs, miRNAs, EGFR, TKI, resistance, NSCLC
Published
2016

177. Transanal endoscopic video-assisted (TEVA) resection of early rectal lesions using a SILS port A single center experience

Author

Calogero, Cipolla, Giuseppina, Ferro, Giuseppa, Graceffa, Lorenzo, Morini, Giuseppina, Guercio, Salvatore, Vieni, and Gianni, Pantuso

Subjects
Adenoma, Adult, Male, Rectal Neoplasms, Video-Assisted Surgery, Length of Stay, Middle Aged, Hospitals, University, Italy, Adenoma, Villous, Humans, Female, Aged, Transanal Endoscopic Surgery
Abstract

represents a safe and complete technique to remove benign lesions of the rectum not treatable by endoscopy and malignant rectal lesions at early stage. It is a valid alternative to transanal endoscopic microsurgery (TEM), to conventional transanal surgery and to transabdominal resection.In our operating Unit we performed a resection of 8 voluminous adenoma in the rectal ampulla with SILSTM-Port.The mean age of the patients was of 51.1 years, the mean BMI was 23. There were not intra or post-operative complications nor conversions to conventional transanal excision or major resective surgery. The postoperative course was normal. The average time of hospitalization was 3 days.TEVA is easier to perform than TEM and does not require a long training and specific and expensive material as the TEM does. TEVA might go to replace completely TEM.Rectal tumours, SILS, TEVA.L’escissione chirurgica endoscopica transanale video-assistita (TEVA) mediante SILSTM– Port (Single Incision Laparoscopic Surgery) si è affermata come una tecnica valida per la rimozione completa di lesioni benigne del retto non trattabili endoscopicamente e per le neoplasie maligne del retto in fase precoce. La TEVA rappresenta una valida alternativa alla escissione microchirurgica transanale (TEM), alla chirurgia transanale convenzionale ed alla resezione transaddominale. Nella nostra Unità Operativa sono state effettuate con successo 8 resezioni di voluminosi adenomi del retto impiegando la tecnica TEVA con con il SILSTM–Port. L’età media dei pazienti è stata di 51,1 anni, il BMI medio è stato di 23. Non sono state registrate complicanze post-operatorie né conversioni verso interventi resettivi maggiori per via trans-addominale. Il decorso post-operatorio dei pazienti è stato regolare. Il tempo medio di ospedalizzazione è stato di 3 giorni. I risultati della nostra esperienza, sia pure poco numerosa, in ci consentono di valutare la tecnica TEVA con SILSTM– Port più semplice da realizzare rispetto alla TEM. La metodica infatti non richiede lunghi periodi di apprendimento né l’impiego di materiale costoso come quello impiegato nella TEM.

Published
2016

178. Factores asociados al estadio clínico avanzado en el inicio de la terapia antirretroviral

Author

Eduardo Warley, Guillermo Fernández Galimberti, María Inés Vieni, Silvina Tavella, Mónica Salas, Javier Desse, Graciela D´Agostino, and Edgardo Szyld

Subjects
lcsh:Immunologic diseases. Allergy, lcsh:R, EstadIo clínico avanzado, lcsh:Medicine, lcsh:RC109-216, Terapia antirretroviral, lcsh:RC581-607, HIV/sida, lcsh:Infectious and parasitic diseases
Abstract

A fin de evaluar la frecuencia y posibles factores asociados a la presencia de estadio clínico avanzado al inicio de terapia antirretroviral (ECAITA), efectuamos un análisis retrospectivo de datos de dos cohortes prospectivas de pacientes infectados por HIV que iniciaron terapia antirretroviral (sin tratamiento anterior) entre 2005 y 2009. Se analizaron las historias clínicas de 264 pacientes, 123 mujeres (46.6%) y 141 hombres (53.4%). La mediana de edad fue de 37.7 años. Observamos ECAITA en 132 casos (50%), de los cuales 102 (77.2%) se asociaron a diagnóstico tardío de infección por HIV y 30 (22.8%) a pacientes con diagnóstico previo no retenidos en el cuidado clínico de la salud. La mediana de células CD4 fue 120/ml y de carga viral 58 038 copias/ml. El recuento de células CD4 era inferior a 200 cel/ml en 174 pacientes (71.3%). Los hombres presentaron ECAITA con mayor frecuencia que las mujeres (59.8% vs. 40.2%), en quienes el diagnóstico se realizó durante el control de un embarazo en el 25.2% de los casos. Consumo elevado de alcohol (p 0.006), ser soltero (p 0.04) y nivel de educación menor al secundario completo (p 0.008) se asociaron a ECAITA en el análisis bivariado. Ser de sexo masculino (p 0.003) fue el único factor asociado tanto en el análisis bivariado como en el multivariado. Nuestros datos refuerzan la necesidad de expandir el testeo para HIV y deberían impulsar a definir acciones programáticas que promuevan el ingreso precoz al cuidado de la infección por HIV.

Published
2012

179. Redefining the intraepithelial lymphocytes threshold to diagnose gluten sensitivity in patients with architecturally normal duodenal histology

Author

Giovanni Tuccari, Gabrio Bassotti, Giuseppe Magazzù, Concetta Sferlazzas, Salvatore Pellegrino, Naire Sansotta, Vincenzo Villanacci, Alessandro Princiotta, Giuseppe Vieni, and Rosa Scarfì

Subjects
medicine.medical_specialty, Pathology, Hepatology, medicine.diagnostic_test, business.industry, Villus Tip, Gastroenterology, Histology, Human leukocyte antigen, medicine.disease, Coeliac disease, Internal medicine, Biopsy, Medicine, Intraepithelial lymphocyte, Pharmacology (medical), Enteropathy, Villous atrophy, business
Abstract

Aliment Pharmacol Ther 2011; 33: 697–706 Summary Background Accuracy of intraepithelial lymphocytes counts for diagnosing mild enteropathy coeliac disease in absence of villous atrophy can be limited by inappropriate controls included in the studies. Aim To determine the diagnostic accuracy of intraepithelial lymphocytes counts utilising controls lacking HLA coeliac disease-associated alleles. Methods Intraepithelial lymphocytes counting at villus tip and per 100 enterocytes was performed at haematoxylin and eosin (H&E) and CD3-stainings in: 29 cases (21 with potential coeliac disease and 8 affected by latent coeliac disease) representing the patient population and 14 noncoeliac controls lacking HLA-DQ2/DQ8 alleles. Results Threshold (mean + 2 s.d.) of duodenal intraepithelial lymphocytes at villus tip and per 100 enterocytes in noncoeliac controls was respectively: 3.5 and 18 at H&E, 3.2 and 17 following CD3-staining. Considering the whole patient population, the sensitivity of tip intraepithelial lymphocytes in detecting mild enteropathy coeliac disease was 90% (95% CI = 72.6–97.8) both at H&E and CD3-stainings. The sensitivity of intraepithelial lymphocytes per 100 enterocytes was 93% (95% CI = 77.2–99.2) both at H&E and CD3-staining. Specificity of both intraepithelial lymphocytes counts was 100% (95% CI = 76.8–100). Using a threshold of 25 intraepithelial lymphocytes per 100 enterocytes could miss 59% of cases at H&E and 48% following CD3-staining. Conclusions Intraepithelial lymphocytes counts are diagnostic feasible tools to detect mild enteropathy coeliac disease. Threshold of duodenal intraepithelial lymphocytes may be lower than currently accepted.

Published
2011
Full Text
View/download PDF

180. Características de la infección por HIV/sida según sexo en una región del Gran Buenos Aires: Períodos 1998-2002/ 2003-2005 Characteristics of HIV infection by sex in a suburban district of Buenos Aires for the periods 1998 to 2002 and 2003 to 2005

Author

Eduardo Warley, Natalia Tamayo Antabak, Javier Desse, Adriana De Luca, Fernando Warley, Mónica Salas, Inés Vieni, Edgardo Szyld, and Debbie Indyk

Subjects
lcsh:Immunologic diseases. Allergy, Healthcare, lcsh:R, Gender differences in HIV infection, HIV, lcsh:Medicine, lcsh:RC109-216, Cuidado de la salud, lcsh:RC581-607, Infección HIV según sexo, lcsh:Infectious and parasitic diseases
Abstract

Con el propósito de evaluar características de la infección por HIV/sida en uno de los distritos más pobres del Gran Buenos Aires, revisamos datos clínicos y epidemiológicos de las historias clínicas de los pacientes con diagnóstico reciente de infección por HIV en el hospital Dr. Diego Paroissien entre 1998 y 2005. Analizamos 524 historias clínicas, 329 (62.8%) correspondientes al período 1998-2002 y 195 (37.2%) al 2003-2005, 241 mujeres (46%) y 283 hombres (54%). El modo dominante de transmisión en las mujeres fue sexual y en los hombres el uso de drogas intravenosas. Las mujeres presentaron al momento del diagnóstico de infección por HIV, de manera estadísticamente significativa, menor estadio clínico, menor edad, mayores valores de recuento de células CD4 y menores de carga viral. No observamos diferencias entre ambos sexos en la frecuencia con que los pacientes continuaron en control clínico al año de seguimiento, iniciaron terapia antirretroviral y continuaron en tratamiento al año de haber iniciado el mismo. Comparando los períodos 1998- 2002 y 2003-2005 se determinó un aumento, estadísticamente significativo, del diagnóstico como parte del control del embarazo en la mujer, del modo primario sexual de adquisición, de la frecuencia de pacientes que continuaron en control clínico al año de seguimiento y de la disminución del uso de drogas inyectables para ambos sexos. Las diferencias de sexo observadas persisten en el período 2003-2005 cuando se excluyeron del análisis las mujeres en las que se realizó el diagnóstico como parte del control del embarazo.With the aim of evaluating gender differences in one of the poorest districts of Buenos Aires, we reviewed epidemiological and clinical data of newly-diagnosed HIV patients at the Diego Paroissien Hospital between 1998 and 2005.We analyzed 524 clinical charts, 329 (62.8%) of which were from the 1998 to 2002 period and 195 (37.2%) from 2003 to 2005. Women accounted for 241 (46%) of the patients. The dominant mode of transmission was sexual intercourse in women and intravenous drug-use in men. At the time of diagnosis, women were at a significantly lower clinical stage, were younger, and had higher CD4 counts and lower viral loads. No gender differences were found in the rates of continued clinical care or continued antiretroviral therapy at one year follow-up. Comparing the periods 1998 to 2002 and 2003 to 2005, there was a statistically significant increase in diagnoses made during the pregnancy screening in women, in sexual transmission as the primary route of HIV infection, in the frequency of patients (both men and women) who had continued clinical care at one year follow-up, and a decreasing of intravenous drug-use in both sexes.The observed gender differences in the 2003-2005 period persisted even when those women who were diagnosed during their pregnancy screening were excluded from the analysis.

Published
2009

182. Surgical Treatment of Extravasation Injuries

Author

NAPOLI, P, CORRADINO, Bartolo, FULFARO, Fabio, TRIPOLI, M, VIENI, Salvatore, CORDOVA, Adriana, MOSCHELLA, Francesco, BADALAMENTI, Giuseppe, NAPOLI, P, CORRADINO, B, FULFARO, F, TRIPOLI, M, VIENI, S, BADALAMENTI, S, CORDOVA, A, MOSCHELLA, F, and Vieni, S.

Subjects
Adult, Male, medicine.medical_specialty, antiblastic, treatment KeyWords Plus:ANTITUMOR AGENTS, extravasation injury, prevention, treatmentANTITUMOR AGENTS, APPROPRIATE MANAGEMENT, TISSUE EXTRAVASATION, HYALURONIDASE [Author Keywords], Drug Extravasation, Therapeutic irrigation, Scars, Antineoplastic Agents, Cicatrix, Biopsy, medicine, Humans, Calciparine, Author Keywords:extravasation injury, Surgical treatment, Therapeutic Irrigation, Aged, Retrospective Studies, medicine.diagnostic_test, business.industry, Biopsy, Needle, General Medicine, HYALURONIDASE, Middle Aged, medicine.disease, Hand, Extravasation, Surgery, Anti-Bacterial Agents, anticancer drugs, Treatment Outcome, Oncology, Anesthesia, Female, medicine.symptom, business, Infiltration (medical), Extravasation of Diagnostic and Therapeutic Materials
Abstract

The authors present their experience of treating anti-cancer drug extravasation by means of a composite surgical technique that consists of infiltration with physiological solution and hyaluronidase and subsequent manual aspiration of solutes alternated with profuse irrigation of the infiltrated area. In the immediate post-op we carry out a medical therapy that consists of calciparine and topic antibiotic and/or steroid creams. Since the year 2000 this technique has been used on 25 patients. We have had neither complications nor scars. Copyright 2005 Wiley-Liss, Inc Surgical treatment of extravasation injuries. Napoli P, Corradino B, Badalamenti G, Tripoli M, Vieni S, Furfaro MF, Cordova A, Moschella F. Source Chirurgia Plastica e Ricostruttiva, Dipartimento di Discipline Chirurgiche ed Oncologiche, Università degli Studi di Palermo, Italy. pietronapoli@libero.it Abstract The authors present their experience of treating anti-cancer drug extravasation by means of a composite surgical technique that consists of infiltration with physiological solution and hyaluronidase and subsequent manual aspiration of solutes alternated with profuse irrigation of the infiltrated area. In the immediate post-op we carry out a medical therapy that consists of calciparine and topic antibiotic and/or steroid creams. Since the year 2000 this technique has been used on 25 patients. We have had neither complications nor scars.

Published
2005

183. Gender Differences in Radiation Dose from Nuclear Cardiology Studies Across the World Findings from the INCAPS Registry

Author

Shi, Lynn, Dorbala, Sharmila, Paez, Diana, Shaw, Leslee J., Zukotynski, Katherine A., Pascual, Thomas N. B., Karthikeyan, Ganesan, Vitola, João V., Better, Nathan, Bokhari, Nadia, Rehani, Madan M., Kashyap, Ravi, Dondi, Maurizio, Mercuri, Mathew, Einstein, Andrew J., Einstein, A. J., Pascual, T. N. B., Paez, D., Dondi, M., Better, N., Bouyoucef, S. E., Karthikeyan, G., Kashyap, R., Lele, V., Magboo, V. P. C., Mahmarian, J. J., Meeks, J. B., Mut, F., Rehani, M. M., Vitola, J. V., Alexanderson, E., Allam, A., Al-Mallah, M. H., Bom, H., Flotats, A., Jerome, S., Kaufmann, P. A., Luxenburg, O., Mahmarian, J., Shaw, L. J., Underwood, S. R., Vitola, J., Amouri, W., Essabbah, H., Gassama, S. S., Makhdomi, K. B., El Mustapha, G. I. E., El Ouchdi, N., Qaïs, N., Soni, N., Vangu, W., Abazid, R. M., Adams, B., Agarwal, V., Alfeeli, M. A., Alnafisi, N., Bernabe, L., Bural, G. G., Chaiwatanarat, T., Chandraguptha, J. M., Cheon, G. J., Cho, I., Dogan, A. S., Eftekhari, M., Frenkel, A., Garty, I., George, S., Geramifar, P., Golan, H., Habib, S., Hussain, R., Im, H., Jeon, H. -J., Kalawat, T., Kang, W. J., Keng, F., Klaipetch, A., Kumar, P. G., Lee, J., Lee, W. W., Lim, I., Macaisa, C. M. M., Malhotra, G., Mittal, B. R., Mohammad, M. H., Mohan, P., Mulyanto, I. D., Nariman, D., Nayak, U. N., Niaz, K., Nikolov, G., Obaldo, J. M., Ozturk, E., Park, J. M., Park, S., Patel, C. D., Phuong, H. K., Quinon, A. P., Rajini, T. R., Saengsuda, Y., Santiago, J., Sayman, H. B., Shinto, A. S., Sivasubramaniyan, V., Son, M. H., Sudhakar, P., Syed, G. M. S., Tamaki, N., Thamnirat, K., Thientunyakit, T., Thongmak, S., Velasco, D. N., Verma, A., Vutrapongwatana, U., Wang, Y., Won, K. S., Yao, Z., Yingsa-Nga, T., Yudistiro, R., Yue, K. T., Zafrir, N., Adrian, S. C., Agostini, D., Aguadé, S., Armitage, G., Backlund, M., Backman, M., Baker, M., Balducci, M. T., Bavelaar, C., Berovic, M., Bertagna, F., Beuchel, R., Biggi, A., Bisi, G., Bonini, R., Bradley, A., Brudin, L., Bruno, I., Busnardo, E., Casoni, R., Choudhri, A., Cittanti, C., Clauss, R., Costa, D. C., Costa, M., Dixon, K., Dziuk, M., Egelic, N., Eriksson, I., Fagioli, G., De Faria, D. B., Florimonte, L., Francini, A., French, M., Gallagher, E., Garai, I., Geatti, O., Genovesi, D., Gianolli, L., Gimelli, A., Del Giudice, E., Halliwell, S., Hansson, M. J., Harrison, C., Homans, F., Horton, F., Jȩdrzejuk, D., Jogi, J., Johansen, A., Johansson, H., Kalnina, M., Kaminek, M., Kiss, A., Kobylecka, M., Kostkiewicz, M., Kropp, J., Kullenberg, R., Lahoutte, T., Lang, O., Larsson, Y. H., Lázár, M., Leccisotti, L., Leners, N., Lindner, O., Lipp, R. W., Maenhout, A., Maffioli, L., Marcassa, C., Martins, B., Marzullo, P., Medolago, G., Mendiguchía, C. G., Mirzaei, S., Mori, M., Nardi, B., Nazarenko, S., Nikoletic, K., Oleksa, R., Parviainen, T., Patrina, J., Peace, R., Pirich, C., Piwowarska-Bilska, H., Popa, S., Prakash, V., Pubul, V., Puklavec, L., Rac, S., Ratniece, M., Rogan, S. A., Romeo, A., Rossi, M., Ruiz, D., Sabharwal, N., Salobir, B. G., Santos, A. I., Saranovic, S., Sarkozi, A., Schneider, R. P., Sciagra, R., Scotti, S., Servini, Z., Setti, L. R., Starck, S. -A., Vajauskas, D., Veselý, J., Vieni, A., Vignati, A., Vito, I. M., Weiss, K., Wild, D., Zdraveska-Kochovska, M., Agüro, R. N., Alvarado, N., Barral, C. M., Beretta, M., Berrocal, I., Batista Cuellar, J. F., Cabral Chang, T. -M., Cabrera Rodríguez, L. O., Canessa, J., Castro Mora, G., Claudia, A. C., Clavelo, G. F., Cruz Júnior, A. F., Faccio, F. F., Fernández, K. M., Gomez Garibo, J. R., Gonzalez, U., González, E. P., Guzzo, M. A., Jofre, J., Kapitán, M., Kempfer, G., Lopez, J. L., Massardo, V. T., Medeiros Colaco, I., Mesquita, C. T., Montecinos, M., Neubauer, S., Pabon, L. M., Puente, A., Rochela Vazquez, L. M., Serna Macias, J. A., Silva Pino, A. G., Tártari Huber, F. Z., Tovar, A. P., Vargas, L., Wiefels, C., Aljizeeri, A., Alvarez, R. J., Barger, D., Beardwood, W., Behrens, J., Brann, L., Brown, D., Carr, H., Churchwell, K., Comingore, G. A., Corbett, J., Costello, M., Cruz, F., Depinet, T., Dorbala, S., Earles, M., Esteves, F. P., Etherton, E., Fanning, R. J., Fornace, J., Franks, L., Gewirtz, H., Gulanchyn, K., Hannah, C. -L., Hays, J., Hendrickson, J., Hester, J., Holmes, K., Johnson, A., Jopek, C., Lewin, H., Lyons, J., Manley, C., Meden, J., Moore, S., Moore, W. H., Murthy, V., Nace, R., Neely, D., Nelson, L., Niedermaier, O., Rice, D., Rigs, R., Schiffer, K., Schockling, E., Schultz, T., Schumacker, T., Sheesley, B., Sheikh, A., Siegel, B., Slim, A. M., Smith, J., Szulc, M., Tanskersley, N., Tilkemeier, P., Valdez, G. D., Vrooman, R., Wawrowicz, D., Winchester, D. E., Alcheikh, A., Allen, B., Atkins, E., Bevan, J., Bonomini, C., Christiansen, J., Clack, L., Craig, E., Dixson, H., Duncan, I., Fredericks, S., Gales, S., Hampson, R., Hanley, T., Hartcher, K., Hassall, J., Kelley, B., Kelly, S., Kidd, T., De Kort, T., Larcos, G., Macdonald, W., Mcgrath, C., Murdoch, E., O'Malley, S., O'Rourke, M., Pack, M., Pearce, R., Praehofer, R., Ramsay, S., Scarlett, L., Smidt, K., Souvannavong, F., Taubman, K., Taylor, G., Tse, K., Unger, S., and Weale, J.

Subjects
gender, nuclear cardiology, radiation exposure, Radiology, Nuclear Medicine and Imaging, Cardiology and Cardiovascular Medicine, Nuclear Medicine and Imaging, Africa, Aged, Asia, Chi-Square Distribution, Coronary Circulation, Cross-Sectional Studies, Europe, Female, Heart Diseases, Humans, Latin America, Linear Models, Logistic Models, Male, Middle Aged, Multivariate Analysis, Myocardial Perfusion Imaging, North America, Oceania, Odds Ratio, Radiopharmaceuticals, Registries, Risk Assessment, Risk Factors, Sex Factors, Healthcare Disparities, Positron-Emission Tomography, Radiation Dosage, Radiation Exposure, Tomography, Emission-Computed, Single-Photon, Radiology, NO
Published
2016

184. Estimating the Reduction in the Radiation Burden From Nuclear Cardiology Through Use of Stress-Only Imaging in the United States and Worldwide

Author

Mathew, Mercuri, Pascual, Thomas N. B., Mahmarian, John J., Shaw, Leslee J., Maurizio, Dondi, Diana, Paez, Einstein, A. J., Pascual, T. N. B., Paez, D., Dondi, M., Better, N., Bouyoucef, S. E., Karthikeyan, G., Kashyap, R., Lele, V., Mut, F., Magboo, V. P. C., Mahmarian, J. J., Mercuri, M., Rehani, M. M., Vitola, J. V., Alexanderson, E., Allam, A., Al-Mallah, M. H., Bom, H., Flotats, A., Jerome, S., Kaufmann, P. A., Luxenburg, O., Mahmarian, J., Shaw, L. J., Underwood, S. R., Vitola, J., Amouri, W., Essabbah, H., Gassama, S. S., Makhdomi, K. B., El Mustapha, G. I. E., El Ouchdi, N., Qaïs, N., Soni, N., Vangu, W., Abazid, R. M., Adams, B., Agarwal, V., Alfeeli, M. A., Alnafisi, N., Bernabe, L., Bural, G. G., Chaiwatanarat, T., Chandraguptha, J. M., Cheon, G. J., Cho, I., Dogan, A. S., Eftekhari, M., Frenkel, A., Garty, I., George, S., Geramifar, P., Golan, H., Habib, S., Hussain, R., Im, H., Jeon, H-J., Kalawat, T., Kang, W. J., Keng, F., Klaipetch, A., Kumar, P. G., Lee, J., Lee, W. W., Lim, I., Macaisa, C. M. M., Malhotra, G., Mittal, B. R., Mohammad, M. H., Mohan, P., Mulyanto, I. D., Nariman, D., Nayak, U. N., Niaz, K., Nikolov, G., Obaldo, J. M., Ozturk, E., Park, J. M., Park, S., Patel, C. D., Phuong, H. K., Quinon, A. P., Rajini, T. R., Saengsuda, Y., Santiago, J., Sayman, H. B., Shinto, A. S., Sivasubramaniyan, V., Son, M. H., Sudhakar, P., Syed, G. M. S., Tamaki, N., Thamnirat, K., Thientunyakit, T., Thongmak, S., Velasco, D. N., Verma, A., Vutrapongwatana, U., Wang, Y., Won, K. S., Yao, Z., Yingsa-nga, T., Yudistiro, R., Yue, K. T., Zafrir, N., Adrian, S. C., Agostini, D., Aguadé, S., Armitage, G., Backlund, M., Backman, M., Baker, M., Balducci, M. T., Bavelaar, C., Berovic, M., Bertagna, F., Beuchel, R., Biggi, A., Bisi, G., Bonini, R., Bradley, A., Brudin, L., Bruno, Iliane Chiara, Busnardo, E., Casoni, R., Choudhri, A., Cittanti, C., Clauss, R., Costa, D. C., Costa, M., Dixon, K., Dziuk, M., Egelic, N., Eriksson, I., Fagioli, G., de Faria, D. B., Florimonte, L., Francini, A., French, M., Gallagher, E., Garai, I., Geatti, O., Genovesi, D., Gianolli, L., Gimelli, A., del Giudice, E., Halliwell, S., Hansson, M. J., Harrison, C., Homans, F., Horton, F., Jędrzejuk, D., Jogi, J., Johansen, A., Johansson, H., Kalnina, M., Kaminek, M., Kiss, A., Kobylecka, M., Kostkiewicz, M., Kropp, J., Kullenberg, R., Lahoutte, T., Lang, O., Larsson, Y. H., Lázár, M., Leccisotti, L., Leners, N., Lindner, O., Lipp, R. W., Maenhout, A., Maffioli, L., Marcassa, C., Martins, B., Marzullo, P., Medolago, G., Meeks, J. B., Mendiguchía, C. G., Mirzaei, S., Mori, M., Nardi, B., Nazarenko, S., Nikoletic, K., Oleksa, R., Parviainen, T., Patrina, J., Peace, R., Pirich, C., Piwowarska-Bilska, H., Popa, S., Prakash, V., Pubul, V., Puklavec, L., Rac, S., Ratniece, M., Rogan, S. A., Romeo, A., Rossi, M., Ruiz, D., Sabharwal, N., Salobir, B. G., Santos, A. I., Saranovic, S., Sarkozi, A., Schneider, R. P., Sciagra, R., Scotti, S., Servini, Z., Setti, L. R., Starck, S. -Å., Vajauskas, D., Veselý, J., Vieni, A., Vignati, A., Vito, I. M., Weiss, K., Wild, D., Zdraveska-Kochovska, M., Agüro, R. N., Alvarado, N., Barral, C. M., Beretta, M., Berrocal, I., Batista Cuellar, J. F., Cabral Chang, T. -M., Cabrera Rodríguez, L. O., Canessa, J., Castro Mora, G., Claudia, A. C., Clavelo, G. F., Cruz Jr, A. F., Faccio, F. F., Fernández, K. M., Gomez Garibo, J. R., Gonzalez, U., González, P., Guzzo, M. A., Jofre, J., Kapitán, M., Kempfer, G., Lopez, J. L., Massardo, T., Medeiros Colaco, I., Mesquita, C. T., Montecinos, M., Neubauer, S., Pabon, L. M., Puente, A., Rochela Vazquez, L. M., Serna Macias, J. A., Silva Pino, A. G., Tártari Huber, F. Z., Tovar, A. P., Vargas, L., Wiefels, C., Aljizeeri, A., Alvarez, R. J., Barger, D., Beardwood, W., Behrens, J., Brann, L., Brown, D., Carr, H., Churchwell, K., Comingore, G. A., Corbett, J., Costello, M., Cruz, F., Depinet, T., Dorbala, S., Earles, M., Esteves, F. P., Etherton, E., Fanning Jr, R. J., Fornace, J., Franks, L., Gewirtz, H., Gulanchyn, K., Hannah, C. -L., Hays, J., Hendrickson, J., Hester, J., Holmes, K., Johnson, A., Jopek, C., Lewin, H., Lyons, J., Manley, C., Meden, J., Moore, S., Moore, W. H., Murthy, V., Nace, R., Neely, D., Nelson, L., Niedermaier, O., Rice, D., Rigs, R., Schiffer, K., Schockling, E., Schultz, T., Schumacker, T., Sheesley, B., Sheikh, A., Siegel, B., Slim, A. M., Smith, J., Szulc, M., Tanskersley, N., Tilkemeier, P., Valdez, G. D., Vrooman, R., Wawrowicz, D., Winchester, D. E., Alcheikh, A., Allen, B., Atkins, E., Bevan, J., Bonomini, C., Christiansen, J., Clack, L., Craig, E., Dixson, H., Duncan, I., Fredericks, S., Gales, S., Hampson, R., Hanley, T., Hartcher, K., Hassall, J., Kelley, B., Kelly, S., Kidd, T., de Kort, T., Larcos, G., Macdonald, W., Mcgrath, C., Murdoch, E., O’Malley, S., O’Rourke, M., Pack, M., Pearce, R., Praehofer, R., Ramsay, S., Scarlett, L., Smidt, K., Souvannavong, F., Taubman, K., Taylor, G., Tse, K., Unger, S., and Weale, J.

Subjects
South asia, business.industry, Coronary arteriosclerosis, Myocardial Perfusion Imaging, 030204 cardiovascular system & hematology, Radiation Dosage, Thallium stress test, Clinical Protocols, Exercise Test, Humans, United States, Internal Medicine, Executive committee, 030218 nuclear medicine & medical imaging, NO, Radiation exposure, 03 medical and health sciences, Kingdom, 0302 clinical medicine, Radiology Specialty, Medicine, business, Humanities
Abstract

Group Information: The INCAPS Investigators Group includes executive committee members A. J. Einstein (chair), T. N. B. Pascual (IAEA project lead), D. Paez (IAEA section head), M. Dondi (IAEA section head); N. Better, S.E. Bouyoucef, G. Karthikeyan, R. Kashyap, V. Lele, F. Mut, V. P. C. Magboo, J. J. Mahmarian, M. Mercuri, M. M. Rehani, and J. V. Vitola, and regional coordinators E. Alexanderson (Latin America), A. Allam (Africa andMiddle East), M. H. Al-Mallah (Middle East), N. Better (Oceania), S. E. Bouyoucef (Africa), H. Bom (East Asia), A. Flotats (Europe), S. Jerome (United States), P. A. Kaufmann (Europe), V. Lele (South Asia), O. Luxenburg (Israel), J. Mahmarian (North America), L. J. Shaw (North America), S. R. Underwood (United Kingdom), and J. Vitola (Latin America). Members by region include W. Amouri, H. Essabbah, S. S. Gassama, K. B. Makhdomi, G. I. E. El Mustapha, N. El Ouchdi, N. Qais, N. Soni, andW. Vangu (Africa); R. M. Abazid, B. Adams, V. Agarwal, M. A. Alfeeli, N. Alnafisi, L. Bernabe, G. G. Bural, T. Chaiwatanarat, J. M. Chandraguptha, G. J. Cheon, I. Cho, A. S. Dogan, M. Eftekhari, A. Frenkel, I. Garty, S. George, P. Geramifar, H. Golan, S. Habib, R. Hussain, H. Im, H-J. Jeon, T. Kalawat, W. J. Kang, F. Keng, A. Klaipetch, P. G. Kumar, J. Lee, W.W. Lee, I. Lim, C. M. M. Macaisa, G. Malhotra, B. R. Mittal, M. H. Mohammad, P. Mohan, I. D. Mulyanto, D. Nariman, U. N. Nayak, K. Niaz, G. Nikolov, J. M. Obaldo, E. Ozturk, J. M. Park, S. Park, C. D. Patel, H. K. Phuong, A. P. Quinon, T. R. Rajini, Y. Saengsuda, J. Santiago, H. B. Sayman, A. S. Shinto, V. Sivasubramaniyan, M. H. Son, P. Sudhakar, G. M. S. Syed, N. Tamaki, K. Thamnirat, T. Thientunyakit, S. Thongmak, D. N. Velasco, A. Verma, U. Vutrapongwatana, Y. Wang, K. S. Won, Z. Yao, T. Yingsa-nga, R. Yudistiro, K. T. Yue, and N. Zafrir (Asia); S. C. Adrian, D. Agostini, S. Aguade, G. Armitage, M. Backlund, M. Backman, M. Baker, M. T. Balducci, C. Bavelaar, M. Berovic, F. Bertagna, R. Beuchel, A. Biggi, G. Bisi, R. Bonini, A. Bradley, L. Brudin, I. Bruno, E. Busnardo, R. Casoni, A. Choudhri, C. Cittanti, R. Clauss, D. C. Costa, M. Costa, K. Dixon, M. Dziuk, N. Egelic, I. Eriksson, G. Fagioli, D. B. de Faria, L. Florimonte, A. Francini, M. French, E. Gallagher, I. Garai, O. Geatti, D. Genovesi, L. Gianolli, A. Gimelli, E. del Giudice, S. Halliwell, M. J. Hansson, C. Harrison, F. Homans, F. Horton, D. Jedrzejuk, J. Jogi, A. Johansen, H. Johansson, M. Kalnina, M. Kaminek, A. Kiss, M. Kobylecka, M. Kostkiewicz, J. Kropp, R. Kullenberg, T. Lahoutte, O. Lang, Y. H. Larsson, M. Lazar, L. Leccisotti, N. Leners, O. Lindner, R. W. Lipp, A. Maenhout, L. Maffioli, C. Marcassa, B. Martins, P. Marzullo, G. Medolago, J. B. Meeks, C. G. Mendiguchia, S. Mirzaei, M. Mori, B. Nardi, S. Nazarenko, K. Nikoletic, R. Oleksa, T. Parviainen, J. Patrina, R. Peace, C. Pirich, H. Piwowarska-Bilska, S. Popa, V. Prakash, V. Pubul, L. Puklavec, S. Rac, M. Ratniece, S. A. Rogan, A. Romeo, M. Rossi, D. Ruiz, N. Sabharwal, B. G. Salobir, A. I. Santos, S. Saranovic, A. Sarkozi, R. P. Schneider, R. Sciagra, S. Scotti, Z. Servini, L. R. Setti, S.-A. Starck, D. Vajauskas, J. Veselý, A. Vieni, A. Vignati, I. M. Vito, K. Weiss, D. Wild, andM. Zdraveska-Kochovska (Europe); R. N. Aguro, N. Alvarado, C. M. Barral, M. Beretta, I. Berrocal, J. F. Batista Cuellar, T.-M. Cabral Chang, L. O. Cabrera Rodriguez, J. Canessa, G. Castro Mora, A. C. Claudia, G. F. Clavelo, A. F. Cruz Jr, F. F. Faccio, K. M. Fernandez, J. R. Gomez Garibo, U. Gonzalez, P. Gonzalez, M. A. Guzzo, J. Jofre, M. Kapitan, G. Kempfer, J. L. Lopez, T. Massardo, I. Medeiros Colaco, C. T. Mesquita, M. Montecinos, S. Neubauer, L. M. Pabon, A. Puente, L. M. Rochela Vazquez, J. A. Serna Macias, A. G. Silva Pino, F. Z. Tartari Huber, A. P. Tovar, L. Vargas, and C. Wiefels (Latin America); A. Aljizeeri, R. J. Alvarez, D. Barger, W. Beardwood, J. Behrens, L. Brann, D. Brown, H. Carr, K. Churchwell, G. A. Comingore, J. Corbett, M. Costello, F. Cruz, T. Depinet, S. Dorbala, M. Earles, F. P. Esteves, E. Etherton, R. J. Fanning Jr, J. Fornace, L. Franks, H. Gewirtz, K. Gulanchyn, C.-L. Hannah, J. Hays, J. Hendrickson, J. Hester, K. Holmes, S. Jerome, A. Johnson, C. Jopek, H. Lewin, J. Lyons, C. Manley, J. Meden, S. Moore, W. H. Moore, V. Murthy, R. Nace, D. Neely, L. Nelson, O. Niedermaier, D. Rice, R. Rigs, K. Schiffer, E. Schockling, T. Schultz, T. Schumacker, B. Sheesley, A. Sheikh, B. Siegel, A. M. Slim, J. Smith, M. Szulc, N. Tanskersley, P. Tilkemeier, G. D. Valdez, R. Vrooman, D. Wawrowicz, and D. E. Winchester (North America); and A. Alcheikh, B. Allen, E. Atkins, J. Bevan, C. Bonomini, J. Christiansen, L. Clack, E. Craig, H. Dixson, I. Duncan, S. Fredericks, S. Gales, R. Hampson, T. Hanley, K. Hartcher, J. Hassall, B. Kelley, S. Kelly, T. Kidd, T. de Kort, G. Larcos, W. Macdonald, C. McGrath, E. Murdoch, S. O’Malley, M. O’Rourke, M. Pack, R. Pearce, R. Praehofer, S. Ramsay, L. Scarlett, K. Smidt, F. Souvannavong, K. Taubman, G. Taylor, K. Tse, S. Unger, and J. Weale (Oceania).

Published
2016

185. Nuclear cardiology practice and associated radiation doses in Europe: results of the IAEA Nuclear Cardiology Protocols Study (INCAPS) for the 27 European countries

Author

Lindner, O., Pascual, Tn, Mercuri, M, Acampa, W, Burchert, W, Flotats, A, Kaufmann, Pa, Kitsiou, A, Knuuti, J, Underwood, Sr, Vitola, Jv, Mahmarian JJ, Karthikeyan, G, Better, N, Rehani, Mm, Kashyap, R, Dondi, M, Paez, D, Einstein, Aj, INCAPS Investigators Group: Pascual TN, Bouyoucef, Se, Lele, V, Magboo, Vp, Mut, F, Mahmarian, Jj, Meeks, Jb, Alexánderson, E, Allam, A, Al-Mallah, Mh, Bom, H, Jerome, S, Luxenburg, O, Mahmarian, J, Shaw, Lj, Vitola, J, Amouri, W, Essabbah, H, Gassama, Ss, Makhdomi, Kb, El Mustapha GI, El Ouchdi, N, Qaïs, N, Soni, N, Vangu, W, Abazid, Rm, Adams, B, Agarwal, V, Alfeeli, Ma, Alnafisi, N, Bernabe, L, Bural, Gg, Chaiwatanarat, T, Chandraguptha, Jm, Cheon, Gj, Cho, I, Dogan, As, Eftekhari, M, Frenkel, A, Garty, I, George, S, Geramifar, P, Golan, H, Habib, S, Hussain, R, Im, H, Jeon, Hj, Kalawat, T, Kang, Wj, Keng, F, Klaipetch, A, Kumar, Pg, Lee, J, Lee, Ww, Lim, I, Macaisa, Cm, Malhotra, G, Mittal, Br, Mohammad, Mh, Mohan, P, Mulyanto, Id, Nariman, D, Nayak, Un, Niaz, K, Nikolov, G, Obaldo, Jm, Ozturk, E, Park, Jm, Park, S, Patel, Cd, Phuong, Hk, Quinon, Ap, Rajini, Tr, Saengsuda, Y, Santiago, J, Sayman, Hb, Shinto, As, Sivasubramaniyan, V, Son, Mh, Sudhakar, P, Syed, Gm, Tamaki, N, Thamnirat, K, Thientunyakit, T, Thongmak, S, Velasco, Dn, Verma, A, Vutrapongwatana, U, Wang, Y, Won, Ks, Yao, Z, Yingsa-nga, T, Yudistiro, R, Yue, Kt, Zafrir, N, Adrian, Sc, Agostini, D, Aguadé, S, Armitage, G, Backlund, M, Backman, M, Baker, M, Balducci, Mt, Bavelaar, C, Berovic, M, Bertagna, F, Beuchel, R, Biggi, A, Bisi, G, Bonini, R, Bradley, A, Brudin, L, Bruno, I, Busnardo, E, Casoni, R, Choudhri, A, Cittanti, C, Clauss, R, Costa, Dc, Costa, M, Dixon, K, Dziuk, M, Egelic, N, Eriksson, I, Fagioli, G, de Faria DB, Florimonte, L, Francini, A, French, M, Gallagher, E, Garai, I, Geatti, O, Genovesi, D, Gianolli, L, Gimelli, A, del Giudice, E, Halliwell, S, Hansson, Mj, Harrison, C, Homans, F, Horton, F, Jędrzejuk, D, Jogi, J, Johansen, A, Johansson, H, Kalnina, M, Kaminek, M, Kiss, A, Kobylecka, M, Kostkiewicz, M, Kropp, J, Kullenberg, R, Lahoutte, T, Lang, O, Larsson, Yh, Lázár, M, Leccisotti, L, Leners, N, Lindner, O, Lipp, Rw, Maenhout, A, Maffioli, L, Marcassa, C, Martins, B, Marzullo, P, Medolago, G, Mendiguchía, Cg, Mirzaei, S, Mori, M, Nardi, B, Nazarenko, S, Nikoletic, K, Oleksa, R, Parviainen, T, Patrina, J, Peace, R, Pirich, C, Piwowarska-Bilska, H, Popa, S, Prakash, V, Pubul, V, Puklavec, L, Rac, S, Ratniece, M, Rogan, Sa, Romeo, A, Rossi, M, Ruiz, D, Sabharwal, N, Salobir, Bg, Santos, Ai, Saranovic, S, Sarkozi, A, Schneider, Rp, Sciagra, R, Scotti, S, Servini, Z, Setti, Lr, Starck, Så, Vajauskas, D, Veselý, J, Vieni, A, Vignati, A, Vito, Im, Weiss, K, Wild, D, Zdraveska-Kochovska, M, Agüro, Rn, Alvarado, N, Barral, Cm, Beretta, M, Berrocal, I, Batista Cuellar JF, Cabral Chang TM, Cabrera Rodríguez LO, Canessa, J, Castro Mora, G, Claudia, Ac, Clavelo, Gf, Cruz Júnior AF, Faccio, Ff, Fernández, Km, Gomez Garibo JR, Gonzalez, U, E P, González, Guzzo, Ma, Jofre, J, Kapitán, M, Kempfer, G, Lopez, Jl, V T, Massardo, Medeiros Colaco, I, Mesquita, Ct, Montecinos, M, Neubauer, S, Pabon, Lm, Puente, A, Rochela Vazquez LM, Serna Macias JA, Silva Pino AG, Tártari Huber FZ, Tovar, Ap, Vargas, L, Wiefels, C, Aljizeeri, A, Alvarez, Rj, Barger, D, Beardwood, W, Behrens, J, Brann, L, Brown, D, Carr, H, Churchwell, K, Comingore, Ga, Corbett, J, Costello, M, Cruz, F, Depinet, T, Dorbala, S, Earles, M, Esteves, Fp, Etherton, E, Fanning RJ Jr, Fornace, J, Franks, L, Gewirtz, H, Gulanchyn, K, Hannah, Cl, Hays, J, Hendrickson, J, Hester, J, Holmes, K, Johnson, A, Jopek, C, Lewin, H, Lyons, J, Manley, C, Meden, J, Moore, S, Moore, Wh, Murthy, V, Nace, R, Neely, D, Nelson, L, Niedermaier, O, Rice, D, Rigs, R, Schiffer, K, Schockling, E, Schultz, T, Schumacker, T, Sheesley, B, Sheikh, A, Siegel, B, Slim, Am, Smith, J, Szulc, M, Tanskersley, N, Tilkemeier, P, Valdez, Gd, Vrooman, R, Wawrowicz, D, Winchester, De, Alcheikh, A, Allen, B, Atkins, E, Bevan, J, Bonomini, C, Christiansen, J, Clack, L, Craig, E, Dixson, H, Duncan, I, Fredericks, S, Gales, S, Hampson, R, Hanley, T, Hartcher, K, Hassall, J, Kelley, B, Kelly, S, Kidd, T, de Kort, T, Larcos, G, Macdonald, W, Mcgrath, C, Murdoch, E, O'Malley, S, O'Rourke, M, Pack, M, Pearce, R, Praehofer, R, Ramsay, S, Scarlett, L, Smidt, K, Souvannavong, F, Taubman, K, Taylor, G, Tse, K, Unger, S, Weale, J., Lindner, Oliver, Pascual, Thomas N. B, Mercuri, Mathew, Acampa, Wanda, Burchert, Wolfgang, Flotats, Albert, Kaufmann, Philipp A, Kitsiou, Anastasia, Knuuti, Juhani, Underwood, S. Richard, Vitola, João V, Mahmarian, John J, Karthikeyan, Ganesan, Better, Nathan, Rehani, Madan M, Kashyap, Ravi, Dondi, Maurizio, Paez, Diana, Einstein, Andrew J., Columbia University Medical Center (CUMC), and Columbia University [New York]

Subjects
INCAPS Investigators Group, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Computed tomography, Best practice, 030204 cardiovascular system & hematology, Myocardial perfusion scintigraphy, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Nuclear Medicine and Imaging, Medicine, media_common, medicine.diagnostic_test, Radiation dose, Scientific, General Medicine, 3. Good health, Patient management, Europe, Nuclear Medicine & Medical Imaging, Radiology Nuclear Medicine and imaging, SPECT, Practice Guidelines as Topic, Cardiology, Original Article, Radiology, Societies, Scientific, medicine.medical_specialty, Best practices, 0299 Other Physical Sciences, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, Radiation Dosage, NO, 03 medical and health sciences, Internal medicine, media_common.cataloged_instance, Radiology, Nuclear Medicine and imaging, Medical physics, European Union, Quality of care, European union, Cardiac Imaging Technique, business.industry, Nuclear cardiology, PET, Cardiac Imaging Techniques, Nuclear Medicine, Positron-Emission Tomography, Radiology, Nuclear Medicine and Imaging, 1103 Clinical Sciences, business, Societies, Medical therapy, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Purpose Nuclear cardiology is widely used to diagnose coronary artery disease and to guide patient management, but data on current practices, radiation dose-related best practices, and radiation doses are scarce. To address these issues, the IAEA conducted a worldwide study of nuclear cardiology practice. We present the European subanalysis. Methods In March 2013, the IAEA invited laboratories across the world to document all SPECT and PET studies performed in one week. The data included age, gender, weight, radiopharmaceuticals, injected activities, camera type, positioning, hardware and software. Radiation effective dose was calculated for each patient. A quality score was defined for each laboratory as the number followed of eight predefined best practices with a bearing on radiation exposure (range of quality score 0 - 8). The participating European countries were assigned to regions (North, East, South, and West). Comparisons were performed between the four European regions and between Europe and the rest-of-the-world (RoW). Results Data on 2,381 European patients undergoing nuclear cardiology procedures in 102 laboratories in 27 countries were collected. A cardiac SPECT study was performed in 97.9 % of the patients, and a PET study in 2.1 %. The average effective dose of SPECT was 8.0 +/- 3.4 mSv (RoW 11.4 +/- 4.3 mSv; P < 0.001) and of PET was 2.6 +/- 1.5 mSv (RoW 3.8 +/- 2.5 mSv; P < 0.001). The mean effective doses of SPECT and PET differed between European regions (P < 0.001 and P = 0.002, respectively). The mean quality score was 6.2 +/- 1.2, which was higher than the RoW score (5.0 +/- 1.1; P < 0.001). Adherence to best practices did not differ significantly among the European regions (range 6 to 6.4; P = 0.73). Of the best practices, stress-only imaging and weight-adjusted dosing were the least commonly used. Conclusion In Europe, the mean effective dose from nuclear cardiology is lower and the average quality score is higher than in the RoW. There is regional variation in effective dose in relation to the best practice quality score. A possible reason for the differences between Europe and the RoW could be the safety culture fostered by actions under the Euratom directives and the implementation of diagnostic reference levels. Stress-only imaging and weight-adjusted activity might be targets for optimization of European nuclear cardiology practice.

Published
2016
Full Text
View/download PDF

186. Comparison of Radiation Doses and Best-Practice Use for Myocardial Perfusion Imaging in US and Non-US Laboratories: Findings From the IAEA (International Atomic Energy Agency) Nuclear Cardiology Protocols Study

Author

Mercuri, Mathew, N B, Pascual Thomas, Mahmarian John, J, Shaw Leslee, J, Rehani Madan, M, Paez, Diana, Einstein, Andrew J, INCAPS Investigators Group: Pascual, T, Paez, D, Dondi, M, Better, N, Bouyoucef, Se, Karthikeyan, G, Kashyap, R, Lele, V, Mut, F, Magboo, V, Mahmarian, J, Mercuri, M, Rehani, M, Vitola, J, Alexanderson, E, Allam, A, Al-Mallah, M, Bouyoucef, S, Bom, H, Flotats, A, Jerome, S, Kaufmann, P, Luxenburg, O, Shaw, L, Underwood, S, Amouri, W, Essabbah, H, Gassama, S, Makhdomi, K, El Mustapha, G, El Ouchdi, N, Qaïs, N, Soni, N, Vangu, W, Abazid, R, Adams, B, Agarwal, V, Alfeeli, M, Alnafisi, N, Bernabe, L, Bural, G, Chaiwatanarat, T, Chandraguptha, J, Cheon, G, Cho, I, Dogan, A, Eftekhari, M, Frenkel, A, Garty, I, George, S, Geramifar, P, Golan, H, Habib, S, Hussain, R, Im, H, Jeon, Hj, Kalawat, T, Kang, W, Keng, F, Klaipetch, A, Kumar, P, Lee, J, Lee, W, Lim, I, Macaisa, C, Malhotra, G, Mittal, B, Mohammad, M, Mohan, P, Mulyanto, I, Nariman, D, Nayak, U, Niaz, K, Nikolov, G, Obaldo, J, Ozturk, E, Park, J, Park, S, Patel, C, Phuong, H, Quinon, A, Rajini, T, Saengsuda, Y, Santiago, J, Sayman, H, Shinto, A, Sivasubramaniyan, V, Son, M, Sudhakar, P, Syed, G, Tamaki, N, Thamnirat, K, Thientunyakit, T, Thongmak, S, Velasco, D, Verma, A, Vutrapongwatana, U, Wang, Y, Won, K, Yao, Z, Yingsa-nga, T, Yudistiro, R, Yue, K, Zafrir, N, Adrian, S, Agostini, D, Aguadé, S, Armitage, G, Backlund, M, Backman, M, Baker, M, Balducci, M, Bavelaar, C, Berovic, M, Bertagna, F, Beuchel, R, Biggi, A, Bisi, G, Bonini, R, Bradley, A, Brudin, L, Bruno, I, Busnardo, E, Casoni, R, Choudhri, A, Cittanti, C, Clauss, R, Costa, D, Costa, M, Dixon, K, Dziuk, M, Egelic, N, Eriksson, I, Fagioli, G, de Faria, D, Florimonte, L, Francini, A, French, M, Gallagher, E, Garai, I, Geatti, O, Genovesi, D, Gianolli, L, Gimelli, A, del Giudice, E, Halliwell, S, Hansson, M, Harrison, C, Homans, F, Horton, F, Jędrzejuk, D, Jogi, J, Johansen, A, Johansson, H, Kalnina, M, Kaminek, M, Kiss, A, Kobylecka, M, Kostkiewicz, M, Kropp, J, Kullenberg, R, Lahoutte, T, Lang, O, Larsson, Y, Lázár, M, Leccisotti, L, Leners, N, Lindner, O, Lipp, R, Maenhout, A, Maffioli, L, Marcassa, C, Martins, B, Marzullo, P, Medolago, G, Meeks, J, Mendiguchía, C, Mirzaei, S, Mori, M, Nardi, B, Nazarenko, S, Nikoletic, K, Oleksa, R, Parviainen, T, Patrina, J, Peace, R, Pirich, C, Piwowarska-Bilska, H, Popa, S, Prakash, V, Pubul, V, Puklavec, L, Rac, S, Ratniece, M, Rogan, S, Romeo, A, Rossi, M, Ruiz, D, Sabharwal, N, Salobir, B, Santos, A, Saranovic, S, Sarkozi, A, Schneider, R, Sciagra, R, Scotti, S, Servini, Z, Setti, L, Starck, Så, Vajauskas, D, Veselý, J, Vieni, A, Vignati, A, Vito, I, Weiss, K, Wild, D, Zdraveska-Kochovska, M, Agüro, R, Alvarado, N, Barral, C, Beretta, M, Berrocal, I, Batista Cuellar, J, Cabral Chang TM, Cabrera Rodríguez, L, Canessa, J, Castro Mora, G, Claudia, A, Clavelo, G, Cruz, A Jr, Faccio, F, Fernández, K, Gomez Garibo, J, Gonzalez, U, González, P, Guzzo, M, Jofre, J, Kapitán, M, Kempfer, G, Lopez, J, Massardo, T, Medeiros Colaco, I, Mesquita, C, Montecinos, M, Neubauer, S, Pabon, L, Puente, A, Rochela Vazquez, L, Serna Macias, J, Silva Pino, A, Tártari Huber, F, Tovar, A, Vargas, L, Wiefels, C, Aljizeeri, A, Alvarez, R, Barger, D, Beardwood, W, Behrens, J, Brann, L, Brown, D, Carr, H, Churchwell, K, Comingore, G, Corbett, J, Costello, M, Cruz, F, Depinet, T, Dorbala, S, Earles, M, Esteves, F, Etherton, E, Fanning, R Jr, Fornace, J, Franks, L, Gewirtz, H, Gulanchyn, K, Hannah, Cl, Hays, J, Hendrickson, J, Hester, J, Holmes, K, Johnson, A, Jopek, C, Lewin, H, Lyons, J, Manley, C, Meden, J, Moore, S, Moore, W, Murthy, V, Nace, R, Neely, D, Nelson, L, Niedermaier, O, Rice, D, Rigs, R, Schiffer, K, Schockling, E, Schultz, T, Schumacker, T, Sheesley, B, Sheikh, A, Siegel, B, Slim, A, Smith, J, Szulc, M, Tanskersley, N, Tilkemeier, P, Valdez, G, Vrooman, R, Wawrowicz, D, Winchester, D, Alcheikh, A, Allen, B, Atkins, E, Bevan, J, Bonomini, C, Christiansen, J, Clack, L, Craig, E, Dixson, H, Duncan, I, Fredericks, S, Gales, S, Hampson, R, Hanley, T, Hartcher, K, Hassall, J, Kelley, B, Kelly, S, Kidd, T, de Kort, T, Larcos, G, Macdonald, W, Mcgrath, C, Murdoch, E, O'Malley, S, O'Rourke, M, Pack, M, Pearce, R, Praehofer, R, Ramsay, S, Scarlett, L, Smidt, K, Souvannavong, F, Taubman, K, Taylor, G, Tse, K, Unger, S, and Weale, J.

Subjects
Male, medicine.medical_specialty, Best practice, 030204 cardiovascular system & hematology, Radiation Dosage, Thallium stress test, 030218 nuclear medicine & medical imaging, NO, 03 medical and health sciences, Myocardial perfusion imaging, 0302 clinical medicine, Clinical Protocols, Internal Medicine, Radiology Specialty, Medical imaging, medicine, Humans, Medical physics, Aged, Female, Middle Aged, Myocardial Perfusion Imaging, Practice Guidelines as Topic, United States, medicine.diagnostic_test, business.industry, Atomic energy, Coronary arteriosclerosis, Radiation exposure, business
Published
2016

188. IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition

Author

Gaggianesi, Miriam, primary, Turdo, Alice, additional, Chinnici, Aurora, additional, Lipari, Elisa, additional, Apuzzo, Tiziana, additional, Benfante, Antonina, additional, Sperduti, Isabella, additional, Di Franco, Simone, additional, Meraviglia, Serena, additional, Lo Presti, Elena, additional, Dieli, Francesco, additional, Caputo, Valentina, additional, Militello, Gabriella, additional, Vieni, Salvatore, additional, Stassi, Giorgio, additional, and Todaro, Matilde, additional

Published
2017
Full Text
View/download PDF

189. Opportunities for improvement on current nuclear cardiology practices and radiation exposure in Latin America: Findings from the 65-country IAEA Nuclear Cardiology Protocols cross-sectional Study (INCAPS)

Author

Vitola, Jv, Mut, F, Alexanderson, E, Pascual, Tnb, Mercuri, M, Karthikeyan, G, Better, N, Rehani, Mm, Kashyap, R, Dondi, M, Paez, D, Einstein, Aj, Bouyoucef, Se, Allam, Ah, Vangu, M, Magboo, Vpc, Mahmarian, Jj, Allam, A, Bom, H, Flotats, A, Jerome, S, Kaufmann, Pa, Lele, V, Luxenburg, O, Mahmarian, J, Shaw, Lj, Underwood, Sr, Amouri, W, Essabbah, H, Gassama, Ss, Makhdomi, Kb, El Mustapha, Gie, El Ouchdi, N, Qaïs, N, Soni, N, Vangu, W, Abazid, Rm, Adams, B, Agarwal, V, Alfeeli, Ma, Alnafisi, N, Bernabe, L, Bural, Gg, Chaiwatanarat, T, Chandraguptha, Jm, Cheon, Gj, Cho, I, Dogan, As, Eftekhari, M, Frenkel, A, Garty, I, George, S, Geramifar, P, Golan, H, Habib, S, Hussain, R, Im, H, Jeon, H-J, Kalawat, T, Kang, Wj, Keng, F, Klaipetch, A, Kumar, Pg, Lee, J, Lee, Ww, Lim, I, Macaisa, Cmm, Malhotra, G, Mittal, Br, Mohammad, Mh, Mohan, P, Mulyanto, Id, Nariman, D, Nayak, Un, Niaz, K, Nikolov, G, Obaldo, Jm, Ozturk, E, Park, Jm, Park, S, Patel, Cd, Phuong, Hk, Quinon, Ap, Rajini, Tr, Saengsuda, Y, Santiago, J, Sayman, Hb, Shinto, As, Sivasubramaniyan, V, Son, Mh, Sudhakar, P, Syed, Gms, Tamaki, N, Thamnirat, K, Thientunyakit, T, Thongmak, S, Velasco, Dn, Verma, A, Vutrapongwatana, U, Wang, Y, Won, Ks, Yao, Z, Yingsa-Nga, T, Yudistiro, R, Yue, Kt, Zafrir, N, Adrian, Sc, Agostini, D, Aguadé, S, Armitage, G, Backlund, M, Backman, M, Baker, M, Balducci, Mt, Bavelaar, C, Berovic, M, Bertagna, F, Beuchel, R, Biggi, A, Bisi, G, Bonini, R, Bradley, A, Brudin, L, Bruno, I, Busnardo, E, Casoni, R, Choudhri, A, Cittanti, C, Clauss, R, Costa, Dc, Costa, M, Dixon, K, Dziuk, M, Egelic, N, Eriksson, I, Fagioli, G, De Faria, Db, Florimonte, L, Francini, A, French, M, Gallagher, E, Garai, I, Geatti, O, Genovesi, D, Gianolli, L, Gimelli, A, Del Giudice, E, Halliwell, S, Hansson, Mj, Harrison, C, Homans, F, Horton, F, Jȩdrzejuk, D, Jogi, J, Johansen, A, Johansson, H, Kalnina, M, Kaminek, M, Kiss, A, Kobylecka, M, Kostkiewicz, M, Kropp, J, Kullenberg, R, Lahoutte, T, Lang, O, Larsson, Yh, Lázár, M, Leccisotti, L, Leners, N, Lindner, O, Lipp, Rw, Maenhout, A, Maffioli, L, Marcassa, C, Martins, B, Marzullo, P, Medolago, G, Mendiguchía, Cg, Mirzaei, S, Mori, M, Nardi, B, Nazarenko, S, Nikoletic, K, Oleksa, R, Parviainen, T, Patrina, J, Peace, R, Pirich, C, Piwowarska-Bilska, H, Popa, S, Prakash, V, Pubul, V, Puklavec, L, Rac, S, Ratniece, M, Rogan, Sa, Romeo, A, Rossi, M, Ruiz, D, Sabharwal, N, Salobir, Bg, Santos, Ai, Saranovic, S, Sarkozi, A, Schneider, Rp, Sciagra, R, Scotti, S, Servini, Z, Setti, Lr, Starck, S-A, Vajauskas, D, Veselý, J, Vieni, A, Vignati, A, Vito, I. M., Weiss, K, Wild, D, Zdraveska-Kochovska, M, Agüro, Rn, Alvarado, N, Barral, Cm, Beretta, M, Berrocal, I, Batista Cuellar, Jf, Cabral Chang, T-M, Cabrera Rodríguez, Lo, Canessa, J, Castro Mora, G, Claudia, Ac, Clavelo, Gf, Cruz, Af, Faccio, Ff, Fernández, Km, Gomez Garibo, Jr, Gonzalez, U, González, Pe, Guzzo, Ma, Jofre, J, Kapitán, M, Kempfer, G, Lopez, Jl, Massardo, Tv, Medeiros Colaco, I, Mesquita, Ct, Montecinos, M, Neubauer, S, Pabon, Lm, Puente, A, Rochela Vazquez, Lm, Serna Macias, Ja, Silva Pino, Ag, Tártari Huber, Fz, Tovar, Ap, Vargas, L, Wiefels, C, Aljizeeri, A, Alvarez, Rj, Barger, D, Beardwood, W, Behrens, J, Brann, L, Brown, D, Carr, H, Churchwell, K, Comingore, Ga, Corbett, J, Costello, M, Cruz, F, Depinet, T, Dorbala, S, Earles, M, Esteves, Fp, Etherton, E, Fanning, Rj, Fornace, J, Franks, L, Gewirtz, H, Gulanchyn, K, Hannah, C-L, Hays, J, Hendrickson, J, Hester, J, Holmes, K, Johnson, A, Jopek, C, Lewin, H, Lyons, J, Manley, C, Meden, J, Moore, S, Moore, Wh, Murthy, V, Nace, R, Neely, D, Nelson, L, Niedermaier, O, Rice, D, Rigs, R, Schiffer, K, Schockling, E, Schultz, T, Schumacker, T, Sheesley, B, Sheikh, A, Siegel, B, Slim, Am, Smith, J, Szulc, Mc, Tanskersley, N, Tilkemeier, P, Valdez, Gd, Vrooman, R, Wawrowicz, D, Winchester, De, Alcheikh, A, Allen, B, Atkins, E, Bevan, J, Bonomini, C, Christiansen, J, Clack, L, Craig, E, Dixson, H, Duncan, I, Fredericks, S, Gales, S, Hampson, R, Hanley, T, Hartcher, K, Hassall, J, Kelley, B, Kelly, S, Kidd, T, De Kort, T, Larcos, G, Macdonald, W, Mcgrath, C, Murdoch, E, O'Malley, S, O'Rourke, M, Pack, M, Pearce, R, Praehofer, R, Ramsay, S, Scarlett, L, Smidt, K, Souvannavong, F, Taubman, K, Taylor, G, Tse, K, Unger, S, and Weale, J

Subjects
best practices, Latin America, Nuclear cardiology, PET, radiation dose, SPECT, Cardiology, Guideline Adherence, Health Care Surveys, Humans, Internationality, Middle Aged, Myocardial Perfusion Imaging, Practice Patterns, Physicians', Quality Assurance, Health Care, Quality Improvement, Radiation Exposure, Radiation Protection, Tomography, Emission-Computed, Utilization Review, medicine.medical_specialty, Latin Americans, Cross-sectional study, Practice Patterns, 030204 cardiovascular system & hematology, Effective dose (radiation), 030218 nuclear medicine & medical imaging, NO, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Medical physics, Tomography, Physicians', Guideline adherence, business.industry, Radiation dose, Coronary heart disease, Radiation exposure, Health Care, Emission-Computed, Radiation protection, Cardiology and Cardiovascular Medicine, business, Quality Assurance
Abstract

Comparison of Latin American (LA) nuclear cardiology (NC) practice with that in the rest of the world (RoW) will identify areas for improvement and lead to educational activities to reduce radiation exposure from NC. INCAPS collected data on all SPECT and PET procedures performed during a single week in March-April 2013 in 36 laboratories in 10 LA countries (n = 1139), and 272 laboratories in 55 countries in RoW (n = 6772). Eight “best practices” were identified a priori and a radiation-related Quality Index (QI) was devised indicating the number used. Mean radiation effective dose (ED) in LA was higher than in RoW (11.8 vs 9.1 mSv, p

Published
2015

190. Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS)

Author

Einstein, Aj, Pascual, Tn, Mercuri, M, Karthikeyan, G, Vitola, Jv, Mahmarian, Jj, Better, N, Bouyoucef, Se, Hee-Seung Bom, H, Lele, V, Magboo, Vp, Alexánderson, E, Allam, Ah, Al-Mallah, Mh, Flotats, A, Jerome, S, Kaufmann, Pa, Luxenburg, O, Shaw, Lj, Underwood, Sr, Rehani, Mm, Kashyap, R, Paez, D, Dondi, M, INCAPS Investigators Group: Einstein AJ, Alexanderson, E, Allam, A, Bom, H, Mahmarian, J, Vitola, J, Amouri, W, Essabbah, H, Gassama, Ss, Makhdomi, Kb, El Mustapha GI, El Ouchdi, N, Qaïs, N, Soni, N, Vangu, W, Abazid, Rm, Adams, B, Agarwal, V, Alfeeli, Ma, Alnafisi, N, Bernabe, L, Bural, Gg, Chaiwatanarat, T, Chandraguptha, Jm, Cheon, Gj, Cho, I, Dogan, As, Eftekhari, M, Frenkel, A, Garty, I, George, S, Geramifar, P, Golan, H, Habib, S, Hussain, R, Im, H, Jeon, Hj, Kalawat, T, Kang, Wj, Keng, F, Klaipetch, A, Kumar, Pg, Lee, J, Lee, Ww, Lim, I, Macaisa, Cm, Malhotra, G, Mittal, Br, Mohammad, Mh, Mohan, P, Mulyanto, Id, Nariman, D, Nayak, Un, Niaz, K, Nikolov, G, Obaldo, Jm, Ozturk, E, Park, Jm, Park, S, Patel, Cd, Phuong, Hk, Quinon, Ap, Rajini, Tr, Saengsuda, Y, Santiago, J, Sayman, Hb, Shinto, As, Sivasubramaniyan, V, Son, Mh, Sudhakar, P, Syed, Gm, Tamaki, N, Thamnirat, K, Thientunyakit, T, Thongmak, S, Velasco, Dn, Verma, A, Vutrapongwatana, U, Wang, Y, Won, Ks, Yao, Z, Yingsa-nga, T, Yudistiro, R, Yue, Kt, Zafrir, N, Adrian, Sc, Agostini, D, Aguadé, S, Armitage, G, Backlund, M, Backman, M, Baker, M, Balducci, Mt, Bavelaar, C, Berovic, M, Bertagna, F, Beuchel, R, Biggi, A, Bisi, G, Bonini, R, Bradley, A, Brudin, L, Bruno, I, Busnardo, E, Casoni, R, Choudhri, A, Cittanti, C, Clauss, R, Costa, Dc, Costa, M, Dixon, K, Dziuk, M, Egelic, N, Eriksson, I, Fagioli, G, de Faria DB, Florimonte, L, Francini, A, French, M, Gallagher, E, Garai, I, Geatti, O, Genovesi, D, Gianolli, L, Gimelli, A, del Giudice, E, Halliwell, S, Hansson, Mj, Harrison, C, Homans, F, Horton, F, Jędrzejuk, D, Jogi, J, Johansen, A, Johansson, H, Kalnina, M, Kaminek, M, Kiss, A, Kobylecka, M, Kostkiewicz, M, Kropp, J, Kullenberg, R, Lahoutte, T, Lang, O, Larsson, Yh, Lázár, M, Leccisotti, L, Leners, N, Lindner, O, Lipp, Rw, Maenhout, A, Maffioli, L, Marcassa, C, Martins, B, Marzullo, P, Medolago, G, Meeks, Jb, Mendiguchía, Cg, Mirzaei, S, Mori, M, Nardi, B, Nazarenko, S, Nikoletic, K, Oleksa, R, Parviainen, T, Patrina, J, Peace, R, Pirich, C, Piwowarska-Bilska, H, Popa, S, Prakash, V, Pubul, V, Puklavec, L, Rac, S, Ratniece, M, Rogan, Sa, Romeo, A, Rossi, M, Ruiz, D, Sabharwal, N, Salobir, Bg, Santos, Ai, Saranovic, S, Sarkozi, A, Schneider, Rp, Sciagra, R, Scotti, S, Servini, Z, Setti, Lr, Starck, Så, Vajauskas, D, Veselý, J, Vieni, A, Vignati, A, Vito, Im, Weiss, K, Wild, D, Zdraveska-Kochovska, M, Agüro, Rn, Alvarado, N, Barral, Cm, Beretta, M, Berrocal, I, Batista Cuellar JF, Cabral Chang TM, Cabrera Rodríguez LO, Canessa, J, Castro Mora, G, Claudia, Ac, Clavelo, Gf, Cruz Júnior AF, Faccio, Ff, Fernández, Km, Gomez Garibo JR, Gonzalez, U, E P, González, Guzzo, Ma, Jofre, J, Kapitán, M, Kempfer, G, Lopez, Jl, V T, Massardo, Medeiros Colaco, I, Mesquita, Ct, Montecinos, M, Neubauer, S, Pabon, Lm, Puente, A, Rochela Vazquez LM, Serna Macias JA, Silva Pino AG, Tártari Huber FZ, Tovar, Ap, Vargas, L, Wiefels, C, Aljizeeri, A, Alvarez, Rj, Barger, D, Beardwood, W, Behrens, J, Brann, L, Brown, D, Carr, H, Churchwell, K, Comingore, Ga, Corbett, J, Costello, M, Cruz, F, Depinet, T, Dorbala, S, Earles, M, Esteves, Fp, Etherton, E, Fanning RJ Jr, Fornace, J, Franks, L, Gewirtz, H, Gulanchyn, K, Hannah, Cl, Hays, J, Hendrickson, J, Hester, J, Holmes, K, Johnson, A, Jopek, C, Lewin, H, Lyons, J, Manley, C, Meden, J, Moore, S, Moore, Wh, Murthy, V, Nace, R, Neely, D, Nelson, L, Niedermaier, O, Rice, D, Rigs, R, Schiffer, K, Schockling, E, Schultz, T, Schumacker, T, Sheesley, B, Sheikh, A, Siegel, B, Slim, Am, Smith, J, Szulc, M, Tanskersley, N, Tilkemeier, P, Valdez, Gd, Vrooman, R, Wawrowicz, D, Winchester, De, Alcheikh, A, Allen, B, Atkins, E, Bevan, J, Bonomini, C, Christiansen, J, Clack, L, Craig, E, Dixson, H, Duncan, I, Fredericks, S, Gales, S, Hampson, R, Hanley, T, Hartcher, K, Hassall, J, Kelley, B, Kelly, S, Kidd, T, de Kort, T, Larcos, G, Macdonald, W, Mcgrath, C, Murdoch, E, O'Malley, S, O'Rourke, M, Pack, M, Pearce, R, Praehofer, R, Ramsay, S, Scarlett, L, Smidt, K, Souvannavong, F, Taubman, K, Taylor, G, Tse, K, Unger, S, and Weale, J.

Subjects
Male, medicine.medical_specialty, Best practices, Cross-sectional study, Cardiology, Global Health, Radiation Dosage, Effective dose (radiation), NO, Myocardial perfusion imaging, Clinical Protocols, Internal medicine, medicine, Humans, Tomography, Nuclear cardiology, PET, Quality of care, Radiation dose, SPECT, Aged, Cross-Sectional Studies, Female, Guideline Adherence, Middle Aged, Myocardial Perfusion Imaging, Positron-Emission Tomography, Practice Guidelines as Topic, Professional Practice, Quality of Health Care, Radiation Exposure, Regression Analysis, Tomography, Emission-Computed, Single-Photon, Cardiology and Cardiovascular Medicine, medicine.diagnostic_test, business.industry, Radiation exposure, Positron emission tomography, Mauriceau–Smellie–Veit maneuver, Observational study, Emission-Computed, business, Single-Photon
Abstract

Aims To characterize patient radiation doses from nuclear myocardial perfusion imaging (MPI) and the use of radiation-optimizing ‘best practices’ worldwide, and to evaluate the relationship between laboratory use of best practices and patient radiation dose. Methods and results We conducted an observational cross-sectional study of protocols used for all 7911 MPI studies performed in 308 nuclear cardiology laboratories in 65 countries for a single week in March–April 2013. Eight ‘best practices’ relating to radiation exposure were identified a priori by an expert committee, and a radiation-related quality index (QI) devised indicating the number of best practices used by a laboratory. Patient radiation effective dose (ED) ranged between 0.8 and 35.6 mSv (median 10.0 mSv). Average laboratory ED ranged from 2.2 to 24.4 mSv (median 10.4 mSv); only 91 (30%) laboratories achieved the median ED ≤ 9 mSv recommended by guidelines. Laboratory QIs ranged from 2 to 8 (median 5). Both ED and QI differed significantly between laboratories, countries, and world regions. The lowest median ED (8.0 mSv), in Europe, coincided with high best-practice adherence (mean laboratory QI 6.2). The highest doses (median 12.1 mSv) and low QI (4.9) occurred in Latin America. In hierarchical regression modelling, patients undergoing MPI at laboratories following more ‘best practices’ had lower EDs. Conclusion Marked worldwide variation exists in radiation safety practices pertaining to MPI, with targeted EDs currently achieved in a minority of laboratories. The significant relationship between best-practice implementation and lower doses indicates numerous opportunities to reduce radiation exposure from MPI globally.

Published
2015

191. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).

Author

Incorvaia, Lorena, Fanale, Daniele, Badalamenti, Giuseppe, Barraco, Nadia, Bono, Marco, Corsini, Lidia Rita, Galvano, Antonio, Gristina, Valerio, Listì, Angela, Vieni, Salvatore, Gori, Stefania, Bazan, Viviana, and Russo, Antonio

Abstract

Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor T cells may be restored through the checkpoint blockade using anti-programmed death 1 or anti-programmed death ligand 1 (PD-L1) antibodies, showing, in several cancer patients, an increased progression-free survival and overall survival compared with classical chemotherapy. As recently shown by several studies, the PD-L1 expression levels in tumors may offer a selection criterion for patients to predict their immunotherapy response. In particular, NSCLC patients with high tumor PD-L1 levels (proportional score ≥ 50% for first-line therapy and ≥ 1% for second-line treatment, respectively) showed better response rates to immunotherapy and longer survival in first-line therapy compared with conventional chemotherapy. PD-L1, whose expression is evaluated by using immunohistochemistry analysis, is currently the only biomarker approved for clinical use in the first- and second-line monotherapy setting and therefore plays a central role in treatment decision-making for patients with advanced NSCLC. In this review we will discuss the key role of PD-L1 as a predictive biomarker of response to pembrolizumab therapy in NSCLC patients by describing the appropriate techniques and methodologies for immunohistochemical evaluation of PD-L1 expression and providing an overview of the clinical studies supporting its predictive significance. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

192. An evaluation score of the difficulty of thyroidectomy considering operating time and preservation of recurrent laryngeal nerve.

Author

Vieni, Salvatore, Graceffa, Giuseppa, Rizzo, Giacomo E. M., Latteri, Federica, Latteri, Mario A., and Cipolla, Calogero

Abstract

The purpose of this study was to edit a renovated thyroidectomy difficulty scale (rTDS) in order to identify underlying thyroid diseases with a longer operative time and higher technical difficulty, also considering preservation of recurrent laryngeal nerve. We developed a renovated scale with a maximum score of 20 points by creating a form in which five variables were considered: vascularity, friability, mobility/fibrosis, gland size and difficulty in preservation of the recurrent laryngeal nerve. Two surgeons separately evaluated each of these. Through a simple linear regression analysis, we have analyzed the relationship between rTDS score and operative times, and between rTDS score and preservation of recurrent nerve. Eventually, Spearman's rank correlation coefficient has been used in order to evaluate our double-blind study. Our cohort included 131 patients undergoing total thyroidectomy. The mean of the rTDS was 9.00 ± 3.67 for Surgeon A and 8.31 ± 3.42 for Surgeon B, with Spearman's rank correlation coefficient between surgeons of 0.85 (p < 0.0001). We have shown that the rTDS score significantly influences the operating times (R2 = 0.44 for surgeon A, R2 = 0.46 for B, p < 0.0001 for both). Moreover, we can say that the rTDS score significantly influences preservation of the recurrent nerve (R2 = 0.37, Beta 0.61, 8.84 t test, p < 0.0001). Our rTDS is a useful tool and, thanks to it, we identified hyperthyroidism and goiter as the hardest underlying disease for surgery. Thus our scale could change operative approach, resulting in better surgeries' scheduling and identification of pathologies that require higher attention. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

193. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.

Author

Beckthold B., Kaye S., Land S., Walker S., Haubrich R., DeJesus E., Berthon-Jones N., Espinosa N., Courtney-Vega K., Absar N., Haskelberg H., Robson R., Donaldson A., Guelman D., Tabrett C., Warzywoda E., MacRae K., Sinclair B., Sinn K., Bloch M., Franic T., Vincent T., Stewart N., Jayewardene A., Dwyer D., Kok J., Assam D., Taylor J., King P., Orth D., Youds D., Sowden D., Johnston C., Murray S., Hehir J., Wadham S., Donohue W., Thompson J., Garsia R., Turnham G., Madden T., Nvene J., Gillies A., Bryant M., Walmsley S., Chan W., LeBlanc R., Lanteigne F., Mouawad R., Rahal I., Guber S., Ozturk S., Smith G., Halpenny R., Reko T., Hills J.R., Allendes G., Hocqueloux F.L., Stephan C., Ebeling F., Spath B., Jensen B.-E.O., Feind C., Meyer-Olson D., Stoll M., Hoeper K., Beider R., Faetkenheur G., Thomas E., Baumgarten A., Ingiliz P., Wienbreyer A., Behrendt D., Nienkarken T., Jessen H., Zedlack C., Simelane S., Assmann J., Ghavami-Kia B., Imahashi M., Tanabe K., Yokomaku Y., Imamura J., de Oca M.M., Gonzalez L., Ponce D., Mendoza A., Sierra-Madero J., Hernandez J.E.S., Ballesteros E.J.R., del Moral Ponce S., Ignatowska A., Bakowska E., Pulik P., Sanz-Moreno J., Paredes R., Puig J., Domingo P., Gutierrez M., Gonzalez-Cordon A., Callau P., Aldeguer J.L., Tovar S.C., Noval M.L., Rivas I., Delgado-Fernandez M., Arribas J.R., Castro J.M., Avihingsanon A., Maek-a-nantawat W., Intasan J., Charoenporn W., Cuprasitrut T., Jaisomkom P., Pruksakaew K., Winston A., Mullaney S., Barbour L., Richardson C., Fox J., Murray T., Teague A., Leen C., Morris S., Satyajit D., Sandhu R., Tucker J., Pett S., Amin J., Horban A., Andrade-Villanueva J., Losso M., Porteiro N., Madero J.S., Belloso W., Tu E., Silk D., Kelleher A., Harrigan R., Clark A., Sugiura W., Wolff M.J., Gill J., Gatell J., Clarke A., Ruxrungtham K., Prazuck T., Kaiser R., Woolley I., Alberto Arnaiz J., Cooper D., Rockstroh J.K., Mallon P., Emery S., Fisher M., Rockstroh J., Stellbrink J., Merlin K., Yeung J., Fsadni B., Marks K., Suzuki K., Rismanto N., Salomon H., Rubio A.E., Chibo D., Birch C., Swenson L., Chan D., Berg T., Obermeier M., Schuelter E., Aragon S.S., Luebke N., Coughlan S., Dean J., Iwatani Y., Teran G.R., Avila S., Sirivichayakul S., Naphassanant M., Ubolyam S., Gambardella L., Valdovinos M., Arnaiz J., Beleta H., Ramos N., Targa M., Boesecke C., Engelhardt A., Perry N., Drummond F., Lefevre E., Corr S., Grant C., Lupo S., Peroni L., Sanchez M., De Paz Sierra M., Viloria G., Parlante A., Bissio E., Luchetti P., Confalonieri V., Warley E., Vieni I., Vilas C., Zarate A., Mayer G., Elliot J., Hagenauer M., Kelley M., Rowling D., Gibson A., Latch N., Beckthold B., Kaye S., Land S., Walker S., Haubrich R., DeJesus E., Berthon-Jones N., Espinosa N., Courtney-Vega K., Absar N., Haskelberg H., Robson R., Donaldson A., Guelman D., Tabrett C., Warzywoda E., MacRae K., Sinclair B., Sinn K., Bloch M., Franic T., Vincent T., Stewart N., Jayewardene A., Dwyer D., Kok J., Assam D., Taylor J., King P., Orth D., Youds D., Sowden D., Johnston C., Murray S., Hehir J., Wadham S., Donohue W., Thompson J., Garsia R., Turnham G., Madden T., Nvene J., Gillies A., Bryant M., Walmsley S., Chan W., LeBlanc R., Lanteigne F., Mouawad R., Rahal I., Guber S., Ozturk S., Smith G., Halpenny R., Reko T., Hills J.R., Allendes G., Hocqueloux F.L., Stephan C., Ebeling F., Spath B., Jensen B.-E.O., Feind C., Meyer-Olson D., Stoll M., Hoeper K., Beider R., Faetkenheur G., Thomas E., Baumgarten A., Ingiliz P., Wienbreyer A., Behrendt D., Nienkarken T., Jessen H., Zedlack C., Simelane S., Assmann J., Ghavami-Kia B., Imahashi M., Tanabe K., Yokomaku Y., Imamura J., de Oca M.M., Gonzalez L., Ponce D., Mendoza A., Sierra-Madero J., Hernandez J.E.S., Ballesteros E.J.R., del Moral Ponce S., Ignatowska A., Bakowska E., Pulik P., Sanz-Moreno J., Paredes R., Puig J., Domingo P., Gutierrez M., Gonzalez-Cordon A., Callau P., Aldeguer J.L., Tovar S.C., Noval M.L., Rivas I., Delgado-Fernandez M., Arribas J.R., Castro J.M., Avihingsanon A., Maek-a-nantawat W., Intasan J., Charoenporn W., Cuprasitrut T., Jaisomkom P., Pruksakaew K., Winston A., Mullaney S., Barbour L., Richardson C., Fox J., Murray T., Teague A., Leen C., Morris S., Satyajit D., Sandhu R., Tucker J., Pett S., Amin J., Horban A., Andrade-Villanueva J., Losso M., Porteiro N., Madero J.S., Belloso W., Tu E., Silk D., Kelleher A., Harrigan R., Clark A., Sugiura W., Wolff M.J., Gill J., Gatell J., Clarke A., Ruxrungtham K., Prazuck T., Kaiser R., Woolley I., Alberto Arnaiz J., Cooper D., Rockstroh J.K., Mallon P., Emery S., Fisher M., Rockstroh J., Stellbrink J., Merlin K., Yeung J., Fsadni B., Marks K., Suzuki K., Rismanto N., Salomon H., Rubio A.E., Chibo D., Birch C., Swenson L., Chan D., Berg T., Obermeier M., Schuelter E., Aragon S.S., Luebke N., Coughlan S., Dean J., Iwatani Y., Teran G.R., Avila S., Sirivichayakul S., Naphassanant M., Ubolyam S., Gambardella L., Valdovinos M., Arnaiz J., Beleta H., Ramos N., Targa M., Boesecke C., Engelhardt A., Perry N., Drummond F., Lefevre E., Corr S., Grant C., Lupo S., Peroni L., Sanchez M., De Paz Sierra M., Viloria G., Parlante A., Bissio E., Luchetti P., Confalonieri V., Warley E., Vieni I., Vilas C., Zarate A., Mayer G., Elliot J., Hagenauer M., Kelley M., Rowling D., Gibson A., and Latch N.

Abstract

Objectives: The Maraviroc Switch (MARCH) study week 48 data demonstrated that maraviroc, a chemokine receptor-5 (CCR5) inhibitor, was a safe and effective switch for the ritonavir-boosted protease inhibitor (PI/r) component of a two nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] plus PI/r-based antiretroviral regimen in patients with R5-tropic virus. Here we report the durability of this finding. Method(s): MARCH, an international, multicentre, randomized, 96-week open-label switch study, enrolled HIV-1-infected adults with R5-tropic virus who were stable (> 24 weeks) and virologically suppressed [plasma viral load (pVL) < 50 HIV-1 RNA copies/mL]. Participants were randomized to continue their current PI/r-based regimen (PI/r) or to switch to MVC plus two N(t)RTIs (MVC) (1:2 randomization). The primary endpoint was the difference in the proportion with pVL < 200 copies/mL at 96 weeks. The switch arm was defined as noninferior if the lower limit of the 95% confidence interval (CI) for the difference was < -12% in the intention-to-treat (ITT) population. Safety endpoints (the difference in the mean change from baseline or a comparison of proportions) were analysed as key secondary endpoints. Result(s): Eighty-two (PI/r) and 156 (MVC) participants were randomized and included in the ITT analysis; 71 (87%) and 130 (83%) were in follow-up and on therapy at week 96. At week 96, 89.0% and 90.4% in the PI/r and MVC arms, respectively, had pVL < 50 copies/mL (95% CI -6.6, 10.2). Moreover, in those switching away from PI/r, there were significant reductions in mean total cholesterol (differences 0.31 mmol/L; P = 0.02) and triglycerides (difference 0.44 mmol/L; P < 0.001). Changes in CD4 T-cell count, renal function, and serious and nonserious adverse events were similar in the two arms. Conclusion(s): MVC as a switch for a PI/r is safe and effective at maintaining virological suppression while having significant lipid benefits over 96 weeks.Copyright © 2017 British H

Published
2017

194. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma

Author

Salvatore Restivo, Nicola Gebbia, Valentina Agnese, Corsale S, Viviana Bazan, Salvatore Vieni, Eva Surmacz, Sandra Cascio, Maria Rosaria Valerio, Fabio Fulfaro, Antonio Russo, Marcella Macaluso, Rosa Maria Tomasino, G. Dardanoni, and Loredana Bruno

Subjects
Genetics, medicine.medical_specialty, Mutation, Physiology, Clinical Biochemistry, Single-strand conformation polymorphism, Cell Biology, Biology, Tp53 mutation, Laryngeal squamous cell carcinoma, medicine.disease_cause, Gastroenterology, Exon, Internal medicine, medicine, S-Phase Fraction, Gene, Dna ploidy
Abstract

ToprospectivelyevaluatetheprognosticsignificanceofTP53,H-,K-,andN-Rasmutations,DNA-ploidyandS-phasefraction(SPF) in patients affected by locally advanced laryngeal squamous cell carcinoma (LSCC). Eight-one patients (median follow-up was 71 months) who underwent resective surgery for primary operable locally advanced LSCC were analyzed. Tumor DNA was screened for mutational analysis by PCR/SSCP and sequencing. DNA-ploidy and SPF were performed byflow cytometric analyses. Thirty-six patients (44%) had, at least, a mutation in the TP53 gene. Of them, 22% (8/36) had double mutations and 3% (1/36) had triplemutations.Intotal,46TP53mutationswereobserved.Themajority(41%)oftheseoccurinexon5(19/46),whilethemutations inexons6,7,and8wererepresentedin14,7,and6patients,respectively(31%,15%,and16%).FiveLSCCpatients(6%)showeda mutation in H-Ras gene. Sixty-three percent of the cases (51/81) were DNA aneuploidy, 14% of these (7/51) were multiclonal. Thirty-ninepatients(48%)hadanhighSPFvalue.AtUnivariateanalysis,theDNAaneuploidy,highSPF(>15.1%),TP53mutations and, in particular, the mutations that occur in exons 5 and 8 were significantly related to quicker disease relapse and short OS. At Multivariate analysis, the major significant predictors for both disease relapse and death were high SPF and any TP53 mutations. While histological grade G3 was an independent factor only for relapse. In conclusions, any TP53 mutations and high SPF are importantbiologicalindicatorstopredicttheoutcomeofLSCCpatients. J.Cell.Physiol.206:181‐188,2006.2005Wiley-Liss,Inc.

Published
2005
Full Text
View/download PDF

195. Validation of a predictive survival model in Italian patients with cystic fibrosis

Author

Valeria Raia, Natalia Cirilli, Enza Montemitro, Giuseppe Vieni, Carla Colombo, Gianfranco Alicandro, Donatello Salvatore, Sara Notarnicola, Alessandro Maria Ferrazza, Laura Minicucci, Vincenzina Lucidi, R. Gagliardini, Serena Quattrucci, Roberto Buzzetti, Giuseppe Magazzù, Gabriella Giordano, Maria Lucia Furnari, Buzzetti, R, Alicandro, G, Minicucci, L, Notarnicola, S, Furnari, Ml, Giordano, G, Lucidi, V, Montemitro, E, Raia, Valeria, Magazzù, G, Vieni, G, Quattrucci, S, Ferrazza, A, Gagliardini, R, Cirilli, N, Salvatore, D, and Colombo, C.

Subjects
Male, Pulmonary and Respiratory Medicine, Pediatrics, medicine.medical_specialty, Adolescent, Population, registry, Cystic fibrosis, survival, Survival models, models, Young Adult, Cystic Fibrosis, Survival, Forced Expiratory Volume, medicine, Humans, Pseudomonas Infections, Pediatrics, Perinatology, and Child Health, education, Survival analysis, cystic fibrosi, education.field_of_study, Chi-Square Distribution, Practice patterns, business.industry, Significant difference, Retrospective cohort study, medicine.disease, Prognosis, Survival Analysis, Logistic Models, Pediatrics, Perinatology and Child Health, Pseudomonas aeruginosa, Registry data, Female, business
Abstract

Background: In 2001 Liou published a 5-year survival model using CFF Registry data. Aims: To evaluate its validity in predicting survival in Italian CF patients. Methods: In a retrospective study on 945 patients, the 9 variables selected by Liou were analyzed, vital status on December 2008 recorded and observed and expected deaths compared. To develop a new model, patients were randomly divided into a derivation (n = 475) and a validation sample (n = 470). Results: A significant difference was found between observed and expected deaths based on Liou's model (62 vs 94), with a 34% reduction in mortality (p < 0.05). A new model (based on FEV1, Staphylococcus aureus and Burkholderia cepacia complex infection, number of pulmonary exacerbations/year) was generated, that correctly predicted survival in the validation sample (31 observed vs 29 expected deaths, p = 0.660). Conclusions: The Liou model did not adequately predict 5-year survival in our CF population that, compared to the one in which it was originally tested, could benefit from 10. years of improvement in treatments and practice patterns. A new generated model, based on only four variables, was more accurate in predicting 5-year survival in Italian CF patients

Published
2012

196. Does the use of fibrin glue prevent seroma formation after axillary lymphadenectomy for breast cancer? A prospective randomized trial in 159 patients

Author

Salvatore Vieni, Salvatore Fricano, Calogero Cipolla, Giuseppa Graceffa, Gaspare Licari, Mario Adelfio Latteri, Adriana Torcivia, Cipolla, C, Fricano, S, Vieni, S, Graceffa, G, Licari, G, Torcivia, A, and Latteri, M

Subjects
Adult, medicine.medical_specialty, medicine.medical_treatment, seroma formation, Breast Neoplasms, Fibrin Tissue Adhesive, Suction, law.invention, breast cancer, Breast cancer, Postoperative Complications, Randomized controlled trial, law, medicine, Humans, In patient, Prospective Studies, Fibrin glue, Mastectomy, Aged, Aged, 80 and over, business.industry, General Medicine, Middle Aged, medicine.disease, Surgery, fibrin glue, Settore MED/18 - Chirurgia Generale, surgical procedures, operative, Seroma, Oncology, Axillary Lymphadenectomy, Axilla, Lymph Node Excision, Female, Tissue Adhesives, axillary lymphadenectomy, business, Quadrantectomy
Abstract

Background Seroma formation frequently occurs in patients who have undergone axillary lymphadenectomy. The aim of the study was to evaluate the effect of fibrin glue in the prevention of seroma formation after axillary lymphadenectomy. Materials and Methods Hundred fifty-nine breast cancer patients about to undergo quadrantectomy or mastectomy plus axillary lymphadenectomy were enrolled in the study and randomized into two groups. Fibrin glue spray applied to the axillary fossa plus placement of closed suction drainage were used in 80 patients (group A); placement of closed suction drainage was only used in 79 patients (group B). Results Group A patients showed a slight advantage with regard to the mean duration of axillary drainage placement (4.5 ± 1.3 days in group A vs. 5.1 ± 1.6 days in group B) and number of seroma aspirations (6.3 ± 1.1 in group A vs. 6.7 ± 1.2 in group B). No statistically significant differences were observed between the two groups of patients regarding the mean volume of total axillary drainage and of total seroma volume. Conclusions The use of fibrin glue does not prevent seroma formation and does not reduce seroma magnitude and duration. The costs of the product involved do not justify its routine use in patients undergoing axillary dissection. J. Surg. Oncol. 2010; 101:600–603. © 2010 Wiley-Liss, Inc.

Published
2010

197. The value of intraoperative frozen section examination of sentinel lymph nodes in surgical management of breast carcinoma

Author

Salvatore Vieni, Daniela Cabibi, Salvatore Fricano, Calogero Cipolla, Irene Gentile, Mario Adelfio Latteri, Cipolla, C, Cabibi, D, Fricano, S, Vieni, S, Gentile, I, and Latteri, M

Subjects
Adult, medicine.medical_specialty, Breast surgery, medicine.medical_treatment, Sentinel lymph node, Breast Neoplasms, Settore MED/08 - Anatomia Patologica, Sensitivity and Specificity, Intraoperative Period, Breast cancer, medicine, Frozen Sections, Humans, Breast, Sentinel lymph node - Frozen section - Intraoperative - Breast carcinoma, Lymph node, Mastectomy, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, business.industry, Sentinel Lymph Node Biopsy, General surgery, Carcinoma, Ductal, Breast, Axillary Lymph Node Dissection, Reproducibility of Results, Middle Aged, medicine.disease, Carcinoma, Lobular, Settore MED/18 - Chirurgia Generale, medicine.anatomical_structure, Lymphatic Metastasis, Axilla, Lymph Node Excision, Surgery, Female, Radiology, Lymph Nodes, business, Breast carcinoma
Abstract

PURPOSE: In breast cancer staging, the need for intraoperative sentinel lymph node (SLN) evaluation has still not been adequately established. This study investigates the impact of intraoperative frozen section (FS) evaluation of SLN to avoid subsequent axillary lymph node dissection (ALND) in patients with positive SLN. METHODS: A retrospective review of 364 breast cancer patients undergoing SLN biopsy with intraoperative FS evaluation of SLN was performed. RESULTS: Sensitivity and accuracy of FS examination of SLN were 76.4% and 94.2%, respectively. The sensitivity was significantly higher in larger tumors (p < 0.01). No significant correlation was found between FS and histologic type. A second intervention was avoided in 83.9% of the patients with positive SLN. CONCLUSIONS: Intraoperative FS examination of the SLN is a useful predictor of axillary lymph node status in breast cancer patients. The majority of SLN-positive patients allows for immediate ALND in a one-stage surgical procedure.

Published
2010

198. Associazione tra i geni identificati sul cromosoma 21q22 ed MHC e la RCU nella popolazione italiana adulta e pediatrica

Author

Palmieri, O, Latiano, A, Valvano, MR, D’Incà, R, Corritore, G, Bossa, F, Caprilli, R, Riegler, G, Catassi, C, Rutigliano, V, Campanozzi, A, Vieni, G, Berni Canani, R, Castiglione, F, Guariso, G, Paese, P, D’Altilia, M, Castro, M, Cucchiara, S, Annese, V., ACCOMANDO, Salvatore, Palmieri, O, Latiano, A, Valvano, MR, D’Incà, R, Corritore, G, Bossa, F, Caprilli, R, Riegler, G, Catassi, C, Rutigliano, V, Campanozzi, A, Vieni, G, Berni Canani, R, Castiglione, F, Guariso, G, Accomando, S, Paese, P, D’Altilia, M, Castro, M, Cucchiara, S, and Annese, V

Subjects
Geni associati, RCU
Published
2009

199. Association between previously identified disease loci at Chr 21q22 and MHC and UC in Italian population

Author

G De Angelis, Renata D'Incà, C. Bascietto, Alessandro Ferraris, Fabrizio Bossa, Maria Rosa Valvano, Maurizio Vecchi, V. F. Annese, Corrado Romano, Giuseppe Corritore, G. Lombardi, Orazio Palmieri, Manuela Pastore, Massimo Castro, G. Vieni, Annamaria Staiano, Anna Latiano, B. Papadatou, Salvatore Cucchiara, Sandro Ardizzone, Salvatore Accomando, Palmieri, O, Latiano, A, Valvano, MR, D’Incà, R, Latiano, T, Corritore, G, Bossa, F, Caprilli, R, Riegler, G, Catassi, C, Rutigliano, V, Campanozzi, A, Vieni, G, Berni Canani, R, Castiglione, F, Guariso, G, Accomando, S, D’Altilia, M, Castro, M, Cucchiara, S, and Annese, V

Subjects
Genetics, Hepatology, biology, business.industry, Association (object-oriented programming), Gastroenterology, biology.protein, Medicine, Ulcerative Colitis, Disease, business, Major histocompatibility complex, Italian population
Published
2009

200. Association Between Previously Identified Disease Loci At Chr12q15 and Chr1p36 and UC in Italian Population

Author

Latiano, Anna, Orazio Palmieri, Valvano, Maria Rosa, D Inca, Renata, Latiano, Tiziana, Corritore, Giuseppe, Colombo, Elisabetta, Bossa, Fabrizio, Guariso, Graziella, Venuto, Domenica, Fries, Walter, Vieni, Giuseppe, Accomando, Salvatore, Canani, R. Berni, Catassi, Carlo, Barabino, Arrigo, Papadatou, Bronislava, Bascietto, Cinzia, Castro, Massimo, Cucchiara, Salvatore, Annese, Vito, Palmieri, O, Latiano, A, Valvano, MR, D’Incà, R, Latiano, T, Corritore, G, Colombo, E, Bossa, F, Guariso, G, De Venuto, D, Fries, W, Vieni, G, Accomando, S, Berni Canani, R, Catassi, C, Barabino, A, Papadatou, B, Bascietto, C, Castro, M, Cucchiara, S, and Annese, V

Subjects
IBD, Disease loci
Published
2009

Catalog

Books, media, physical & digital resources
See catalog results